UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)



☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June 30, 2019~~March 31, 2020



☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-4802

Becton, Dickinson and Company

(Exact name of registrant as specified in its charter)



New Jersey				22-0760120
(State or other jurisdiction of incorporation or organization)				(I.R.S. Employer Identification No.)

1 Becton Drive,	Franklin Lakes,	New Jersey	07417-1880	(201)	847-6800
(Address of principal executive offices) (Zip Code)				(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:



Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common stock, par value $1.00	BDX	~~New York Stock Exchange~~
~~Depositary Shares, each representing 1/20th of a share of 6.125% Cumulative Preferred Stock Series A~~	~~BDXA~~	New York Stock Exchange
1.000% Notes due December 15, 2022	BDX22A	New York Stock Exchange
1.900% Notes due December 15, 2026	BDX26	New York Stock Exchange
1.401% Notes due May 24, 2023	BDX23A	New York Stock Exchange
3.020% Notes due May 24, 2025	BDX25	New York Stock Exchange
0.174% Notes due June 4, 2021	BDX/21	New York Stock Exchange
0.632% Notes due June 4, 2023	BDX/23A	New York Stock Exchange
1.208% Notes due June 4, 2026	BDX/26A	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.



Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.			☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

There were ~~269,954,141~~271,776,378 shares of Common Stock, $1.00 par value, outstanding at ~~June 30, 2019.~~March 31, 2020.

BECTON, DICKINSON AND COMPANY

FORM 10-Q

For the quarterly period ended ~~June 30, 2019~~March 31, 2020

TABLE OF CONTENTS



		Page Number
Part I.	FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)
	Condensed Consolidated Balance Sheets	3
	Condensed Consolidated Statements of Income (Loss)	4
	Condensed Consolidated Statements of Comprehensive Income (Loss)	5
	Condensed Consolidated Statements of Cash Flows	6
	Notes to Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2422
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3837
Item 4.	Controls and Procedures	3837

Part II.	OTHER INFORMATION

Item 1.	Legal Proceedings	3938
Item 1A.	Risk Factors	4039
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4039
Item 3.	Defaults Upon Senior Securities	4140
Item 4.	Mine Safety Disclosures	4140
Item 5.	Other Information	4140
Item 6.	Exhibits	4140

Signatures		42

~~Exhibits~~		4341

ITEM 1. FINANCIAL STATEMENTS

BECTON, DICKINSON AND COMPANY

CONDENSED CONSOLIDATED BALANCE SHEETS

Millions of dollars


	June 30, 2019			September 30, 2018			March 31, 2020			September 30, 2019
Assets	(Unaudited)						(Unaudited)
Current Assets:
Cash and equivalents	$	523		$	1,140		$	2,351		$	536
Restricted cash	71			96			88			54
Short-term investments	12			17			6			30
Trade receivables, net	2,220			2,319			2,160			2,345
Inventories:
Materials	569			510			601			544
Work in process	317			297			357			318
Finished products	1,743			1,644			1,836			1,717
	2,629			2,451			2,793			2,579
Assets held for sale	—			137
Prepaid expenses and other	1,326			1,251			1,156			1,119
Total Current Assets	6,781			7,411			8,555			6,664
Property, Plant and Equipment	11,040			10,485			11,262			11,128
Less allowances for depreciation and amortization	5,491			5,111			5,598			5,469
Property, Plant and Equipment, Net	5,550			5,375			5,664			5,659
Goodwill	23,498			23,600			23,415			23,376
Developed Technology, Net	11,334			12,184			10,545			11,054
Customer Relationships, Net	3,507			3,723			3,261			3,424
Other Intangibles, Net	500			534			567			500
Other Assets	1,063			1,078			1,509			1,088
Total Assets	$	52,233		$	53,904		$	53,516		$	51,765
Liabilities and Shareholders’ Equity
Current Liabilities:
Short-term debt	$	2,168		$	2,601		$	4,357		$	1,309
Payables and accrued expenses	4,069			4,615
Payables, accrued expenses and other current liabilities							4,398			4,345
Total Current Liabilities	6,237			7,216			8,755			5,655
Long-Term Debt	18,016			18,894			16,809			18,081
Long-Term Employee Benefit Obligations	862			1,056			1,253			1,272
Deferred Income Taxes and Other	5,621			5,743
Deferred Income Taxes and Other Liabilities							5,747			5,676
Commitments and Contingencies (See Note 5)
Shareholders’ Equity
Preferred stock	2			2			2			2
Common stock	347			347			347			347
Capital in excess of par value	16,227			16,179			16,288			16,270
Retained earnings	12,997			12,596			12,868			12,913
Deferred compensation	23			22			23			23
Common stock in treasury - at cost	(6,201		)	(6,243		)	(6,158		)	(6,190		)
Accumulated other comprehensive loss	(1,897		)	(1,909		)	(2,419		)	(2,283		)
Total Shareholders’ Equity	21,497			20,994			20,951			21,081
Total Liabilities and Shareholders’ Equity	$	52,233		$	53,904		$	53,516		$	51,765

Amounts may not add due to rounding.

See notes to condensed consolidated financial statements

BECTON, DICKINSON AND COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

Millions of dollars, except per share data

(Unaudited)


	Three Months Ended June 30,						Nine Months Ended June 30,						Three Months Ended March 31,						Six Months Ended March 31,
	2019			2018			2019			2018			2020			2019			2020			2019
Revenues	$	4,350		$	4,278		$	12,706		$	11,581		$	4,253		$	4,195		$	8,479		$	8,355
Cost of products sold	2,276			2,262			6,684			6,405			2,520			2,221			4,766			4,408
Selling and administrative expense	1,076			1,086			3,238			2,915			1,025			1,089			2,146			2,161
Research and development expense	282			277			792			727			264			252			535			510
Acquisitions and other restructurings	90			142			281			600			75			101			161			191
Other operating expense, net	—			—			61			—			—			396			—			61
Total Operating Costs and Expenses	3,725			3,767			11,056			10,647			3,884			4,059			7,607			7,332
Operating Income	626			512			1,649			933			370			136			871			1,024
Interest expense	(156		)	(182		)	(498		)	(525		)	(134		)	(171		)	(270		)	(342		)
Interest income	2			8			8			55			2			18			3			6
Other (expense) income, net	(11		)	310			19			295			(38		)	20			(11		)	30
Income Before Income Taxes	460			647			1,178			759			200			3			594			718
Income tax provision	9			53			107			313
Income tax provision (benefit)													17			(17		)	134			98
Net Income	451			594			1,071			446			183			20			461			619
Preferred stock dividends	(38		)	(38		)	(114		)	(114		)	(38		)	(38		)	(76		)	(76		)
Net income applicable to common shareholders	$	413		$	556		$	957		$	332
Net income (loss) applicable to common shareholders													$	145		$	(18	)	$	385		$	544


Basic Earnings per Share	$	1.53		$	2.08		$	3.55		$	1.30
Diluted Earnings per Share	$	1.51		$	2.03		$	3.49		$	1.27
Basic Earnings (Loss) per Share													$	0.53		$	(0.07	)	$	1.42		$	2.02
Diluted Earnings (Loss) per Share													$	0.53		$	(0.07	)	$	1.40		$	1.98
Dividends per Common Share	$	0.77		$	0.75		$	2.31		$	2.25		$	0.79		$	0.77		$	1.58		$	1.54

Amounts may not add due to rounding.

See notes to condensed consolidated financial statements

BECTON, DICKINSON AND COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

Millions of dollars

(Unaudited)


	Three Months Ended June 30,						Nine Months Ended June 30,						Three Months Ended March 31,						Six Months Ended March 31,
	2019			2018			2019			2018			2020			2019			2020			2019
Net Income	$	451		$	594		$	1,071		$	446		$	183		$	20		$	461		$	619
Other Comprehensive (Loss) Income, Net of Tax
Foreign currency translation adjustments	(68		)	(214		)	(27		)	(122		)	(125		)	76			(99		)	42
Defined benefit pension and postretirement plans	12			16			40			(57		)	17			13			33			28
Cash flow hedges	(3		)	1			(2		)	—			(109		)	(1		)	(70		)	—
Other Comprehensive (Loss) Income, Net of Tax	(58		)	(197		)	12			(179		)	(218		)	88			(136		)	70
Comprehensive Income	$	393		$	397		$	1,082		$	267
Comprehensive (Loss) Income													$	(35	)	$	108		$	325		$	689

Amounts may not add due to rounding.

See notes to condensed consolidated financial statements

BECTON, DICKINSON AND COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Millions of dollars

(Unaudited)


	Nine Months Ended June 30,						Six Months Ended March 31,
	2019			2018			2020			2019
Operating Activities
Net income	$	1,071		$	446		$	461		$	619
Adjustments to net income to derive net cash provided by operating activities:
Depreciation and amortization	1,700			1,412			1,067			1,126
Share-based compensation	208			261			141			152
Deferred income taxes	(172		)	(472		)	(136		)	(109		)
Change in operating assets and liabilities	(661		)	430			(258		)	(531		)
Pension obligation	(150		)	(228		)	49			(202		)
Excess tax benefits from payments under share-based compensation plans	45			63
Gain on sale of Vyaire interest	—			(308		)
Gain on sale of business	(336		)	—			—			(335		)
Product liability-related charge	331			—			—			331
Other, net	(77		)	(45		)	(128		)	(25		)
Net Cash Provided by Operating Activities	1,959			1,559			1,196			1,027
Investing Activities
Capital expenditures	(599		)	(588		)	(395		)	(362		)
Proceeds from sale of investments, net	4			13
Acquisitions of businesses, net of cash acquired	—			(14,998		)
Proceeds from divestitures, net	477			534			—			477
Other, net	(182		)	(133		)	(147		)	(85		)
Net Cash Used for Investing Activities	(300		)	(15,173		)
Net Cash (Used for) Provided by Investing Activities							(542		)	30
Financing Activities
Change in credit facility borrowings	300			200			210			—
Proceeds from long-term debt and term loans	2,224			4,335			1,900			—
Payments of debt and term loans	(3,882		)	(2,723		)	(305		)	(905		)
Dividends paid	(737		)	(687		)	(505		)	(491		)
Other, net	(204		)	(176		)	(90		)	(135		)
Net Cash (Used for) Provided by Financing Activities	(2,300		)	949
Net Cash Provided by (Used for) Financing Activities							1,210			(1,532		)
Effect of exchange rate changes on cash and equivalents and restricted cash	(1		)	(5		)	(15		)	5
Net decrease in cash and equivalents and restricted cash	(642		)	(12,670		)
Net increase (decrease) in cash and equivalents and restricted cash							1,849			(469		)
Opening Cash and Equivalents and Restricted Cash	1,236			14,179			590			1,236
Closing Cash and Equivalents and Restricted Cash	$	594		$	1,509		$	2,439		$	767

Non-Cash Investing Activities
Fair value of shares issued as acquisition consideration	$	—		$	8,004
Fair value of equity awards issued as acquisition consideration	$	—		$	613

Amounts may not add due to rounding.

See notes to condensed consolidated financial statements

BECTON, DICKINSON AND COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~June 30, 2019~~March 31, 2020

Note 1 – Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, in the opinion of the management of Becton, Dickinson and Company (the "Company" or "BD"), include all adjustments which are of a normal recurring nature, necessary for a fair presentation of the financial position and the results of operations and cash flows for the periods presented. However, the financial statements do not include all information and accompanying notes required for a presentation in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s ~~2018~~2019 Annual Report on Form 10-K. Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

Note 2 – Accounting Changes

New Accounting ~~Principles~~Principle Adopted

On October 1, 2018, the Company adopted Accounting Standards Codification Topic 606, "Revenue from Contracts with Customers" ("ASC 606") using the modified retrospective method. Under ASC 606, revenue is recognized upon the transfer of control of goods or services to customers and reflects the amount of consideration to which a reporting entity expects to be entitled in exchange for those goods or services. The Company assessed the impact of this new standard on its consolidated financial statements based upon a review of contracts that were not completed as of October 1, 2018. Amounts presented in the Company's financial statements for the prior-year periods have not been revised and are reflective of the revenue recognition requirements which were in effect for those periods. This accounting standard adoption, which is further discussed in Note 6, did not materially impact any line items of the Company's consolidated income statements and balance sheet.

On October 1, 2018, the Company retrospectively adopted an accounting standard update which requires all components of net periodic pension and postretirement benefit costs to be disaggregated from the service cost component and to be presented on the income statement outside a subtotal of income from operations, if one is presented. Upon the Company's adoption of the accounting standard update, which did not have a material impact on its consolidated financial statements, all components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost, are recorded to ~~Other income (expense), net~~ ~~on its consolidated income statements for all periods presented. Revisions of prior-year period amounts were estimated based upon previously disclosed amounts.~~

On October 1, 2018, the Company adopted an accounting standard update which requires that the income tax effects of intercompany sales or transfers of assets, except those involving inventory, be recognized in the income statement as income tax expense (or benefit) in the period that the sale or transfer occurs. The Company adopted this accounting standard update, which did not have a material impact on its consolidated financial statements, using the modified retrospective method.

~~New Accounting Principle Not Yet Adopted~~

In February 2016, the ~~FASB~~Financial Accounting Standards Board ("FASB") issued a new lease accounting standard which requires lessees to recognize lease assets and lease liabilities on the balance ~~sheet. The new standard also~~sheet, as well as requires expanded disclosures regarding leasing arrangements. The Company is in the process of evaluating the impact on its consolidated financial statements and anticipates most of its current operating leases will result in the recognition of right-of-use assets and corresponding lease liabilities on its consolidated balance sheet. The new standard is not expected to materially impact the Company's results of operations. The Company will adopt theadopted this standard on October 1, 2019 and ~~will elect~~elected certain practical expedients permitted under the transition guidance, including a transition method ~~that~~which allows application of the new standard at its adoption date, rather than at the earliest comparative period presented in the financial statements. The Company also elected not to perform any reassessments relative to its expired and existing leases upon its adoption of the new requirements. The Company's adoption of this standard did not materially impact its condensed consolidated financial statements. Additional disclosures regarding the Company’s lease arrangements are provided in Note 15.

New Accounting Principles Not Yet Adopted

In June 2016, the FASB issued a new accounting standard which requires earlier recognition of credit losses on loans and other financial instruments held by entities, including trade receivables. The new standard requires entities to measure all expected credit losses for financial assets held at each reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption on October 1, 2020.

In August 2018, the FASB issued a new accounting standard to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The standard is effective for the Company on October 1, 2020, but early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption.

Note 3 – Shareholders' Equity

Changes in certain components of shareholders' equity for the first ~~three~~two quarters of fiscal years ~~2019~~2020 and ~~2018~~2019 were as follows:

Common
Stock Issued
at Par Value

Capital in
Excess of
Par Value

Retained
Earnings

Deferred
Compensation
Treasury Stock
(Millions of dollars)
Shares (in
thousands)
Amount
Balance at September 30, 2018 $ 347
$ 16,179
$ 12,596
$ 22
(78,463 ) $ (6,243 )
Net income —
—
599
—
—
—
Common dividends ($0.77 per share) —
—
(207 ) —
—
—
Preferred dividends —
—
(38 ) —
—
—
Common stock issued for share-based compensation and other plans, net —
(97 ) —
2
851
9
Share-based compensation —
92
—
—
—
—
Common stock held in trusts, net (a) —
—
—
—
(12 ) —
Effect of changes in accounting principles (see Note 2) —
—
68
—
—
—
Balance at December 31, 2018 $ 347
$ 16,174
$ 13,018
$ 24
(77,624 ) $ (6,235 )
Net income —
—
20
—
—
—
Common dividends ($0.77 per share) —
—
(208 ) —
—
—
Preferred dividends —
—
(38 ) —
—
—
Common stock issued for share-based compensation and other plans, net —
(57 ) (1 ) (1 ) 618
42
Share-based compensation —
60
—
—
—
—
Common stock held in trusts, net (a) —
—
—
—
50
—
Balance at March 31, 2019 $ 347
$ 16,177
$ 12,792
$ 23
(76,955 ) $ (6,192 )
Net income —
—
451
—
—
—
Common dividends ($0.77 per share) —
—
(208 ) —
—
—
Preferred dividends —
—
(38 ) —
—
—
Common stock issued for share-based compensation and other plans, net —
(6 ) —
—
219
(8 )
Share-based compensation —
56
—
—
—
—
Common stock held in trusts, net (a) —
—
—
—
4
—
Balance at June 30, 2019 $ 347
$ 16,227
$ 12,997
$ 23
(76,733 ) $ (6,201 )



	Common Stock Issued at Par Value		Capital in Excess of Par Value			Retained Earnings			Deferred Compensation			Treasury Stock
(Millions of dollars)	Common Stock Issued at Par Value		Capital in Excess of Par Value			Retained Earnings			Deferred Compensation			Shares (in thousands)		Amount
Balance at September 30, 2019	$	347	$	16,270		$	12,913		$	23		(76,260	)	$	(6,190	)
Net income	—		—			278			—			—		—
Common dividends ($0.79 per share)	—		—			(215		)	—			—		—
Preferred dividends	—		—			(38		)	—			—		—
Common stock issued for share-based compensation and other plans, net	—		(32		)	—			1			758		(38		)
Share-based compensation	—		82			—			—			—		—
Common stock held in trusts, net (a)	—		—			—			—			(12	)	—
Balance at December 31, 2019	$	347	$	16,320		$	12,938		$	24		(75,514	)	$	(6,228	)
Net income	—		—			183			—			—		—
Common dividends ($0.79 per share)	—		—			(215		)	—			—		—
Preferred dividends	—		—			(38		)	—			—		—
Common stock issued for share-based compensation and other plans, net	—		(91		)	—			(1		)	573		70
Share-based compensation	—		58			—			—			—		—
Common stock held in trusts, net (a)	—		—			—			—			30		—
Balance at March 31, 2020	$	347	$	16,288		$	12,868		$	23		(74,911	)	$	(6,158	)


	Common Stock Issued at Par Value		Capital in Excess of Par Value			Retained Earnings			Deferred Compensation		Treasury Stock					Common Stock Issued at Par Value		Capital in Excess of Par Value			Retained Earnings			Deferred Compensation			Treasury Stock
(Millions of dollars)	Common Stock Issued at Par Value		Capital in Excess of Par Value			Retained Earnings			Deferred Compensation		Shares (in thousands)		Amount			Common Stock Issued at Par Value		Capital in Excess of Par Value			Retained Earnings			Deferred Compensation			Shares (in thousands)		Amount
Balance at September 30, 2017	$	347	$	9,619		$	13,111		$	19	(118,745	)	$	(8,427	)
Net loss	—		—			(136		)	—		—		—
Common dividends ($0.75 per share)	—		—			(172		)	—		—		—
Preferred dividends	—		—			(38		)	—		—		—
Common stock issued for acquisition	—		6,487			—			—		37,306		2,121
Common stock issued for share-based compensation and other plans, net	—		(51		)	—			—		1,021		(37		)
Share-based compensation	—		142			—			—		—		—
Common stock held in trusts, net (a)	—		—			—			—		(27	)	—
Balance at December 31, 2017	$	347	$	16,197		$	12,765		$	19	(80,445	)	$	(6,343	)
Net loss	—		—			(12		)	—		—		—
Common dividends ($0.75 per share)	—		—			(201		)	—		—		—
Preferred dividends	—		—			(38		)	—		—		—
Common stock issued for acquisition	—		(9		)	—			—		—		—
Common stock issued for share-based compensation and other plans, net	—		(94		)	(1		)	2		943		44
Share-based compensation	—		76			—			—		—		—
Common stock held in trusts, net (a)	—		—			—			—		17		—
Effect of changes in accounting principles	—		—			103			—		—		—
Balance at March 31, 2018	$	347	$	16,170		$	12,616		$	21	(79,485	)	$	(6,300	)
Balance at September 30, 2018																$	347	$	16,179		$	12,596		$	22		(78,463	)	$	(6,243	)
Net income	—		—			594			—		—		—			—		—			599			—			—		—
Common dividends ($0.75 per share)	—		—			(201		)	—		—		—
Common dividends ($0.77 per share)																—		—			(207		)	—			—		—
Preferred dividends	—		—			(38		)	—		—		—			—		—			(38		)	—			—		—
Common stock issued for share-based compensation and other plans, net	—		(25		)	(1		)	1		364		24			—		(97		)	—			2			851		9
Share-based compensation	—		48			—			—		—		—			—		92			—			—			—		—
Common stock held in trusts, net (a)	—		—			—			—		(2	)	—			—		—			—			—			(12	)	—
Balance at June 30, 2018	$	347	$	16,193		$	12,971		$	22	(79,124	)	$	(6,275	)
Effect of change in accounting principles																—		—			68			—			—		—
Balance at December 31, 2018																$	347	$	16,174		$	13,018		$	24		(77,624	)	$	(6,235	)
Net income																—		—			20			—			—		—
Common dividends ($0.77 per share)																—		—			(208		)	—			—		—
Preferred dividends																—		—			(38		)	—			—		—
Common stock issued for share-based compensation and other plans, net																—		(57		)	(1		)	(1		)	618		42
Share-based compensation																—		60			—			—			—		—
Common stock held in trusts, net (a)																—		—			—			—			50		—
Balance at March 31, 2019																$	347	$	16,177		$	12,792		$	23		(76,955	)	$	(6,192	)


(a)	Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan.

The components and changes of Accumulated other comprehensive income (loss) for the first ~~three~~two quarters of fiscal years ~~2019~~2020 and ~~2018~~2019 were as follows:

(Millions of dollars) Total
Foreign Currency
Translation
Benefit Plans

Cash Flow Hedges
Balance at September 30, 2018 $ (1,909 ) $ (1,162 ) $ (729 ) $ (17 )
Other comprehensive (loss) income before reclassifications, net of taxes (32 ) (35 ) 3
(1 )
Amounts reclassified into income, net of taxes 14
—
13
1
Balance at December 31, 2018 $ (1,927 ) $ (1,197 ) $ (714 ) $ (16 )
Other comprehensive income (loss) before reclassifications, net of taxes 74
76
—
(2 )
Amounts reclassified into income, net of taxes 14
—
13
1
Balance at March 31, 2019 $ (1,839 ) $ (1,121 ) $ (701 ) $ (17 )
Other comprehensive loss before reclassifications, net of taxes (68 ) (68 ) —
—
Amounts reclassified into income, net of taxes 10
—
12
(2 )
Balance at June 30, 2019 $ (1,897 ) $ (1,189 ) $ (689 ) $ (19 )



(Millions of dollars)	Total			Foreign Currency Translation			Benefit Plans			Cash Flow Hedges
Balance at September 30, 2019	$	(2,283	)	$	(1,256	)	$	(1,005	)	$	(23	)
Other comprehensive income before reclassifications, net of taxes	63			26			—			37
Amounts reclassified into income, net of taxes	19			—			17			2
Balance at December 31, 2019	$	(2,202	)	$	(1,230	)	$	(988	)	$	16
Other comprehensive loss before reclassifications, net of taxes	(237		)	(125		)	—			(111		)
Amounts reclassified into income, net of taxes	19			—			17			2
Balance at March 31, 2020	$	(2,419	)	$	(1,355	)	$	(971	)	$	(93	)

(Millions of dollars) Total
Foreign Currency
Translation
Benefit Plans

Cash Flow Hedges
Balance at September 30, 2017 $ (1,723 ) $ (1,001 ) $ (703 ) $ (18 )
Other comprehensive loss before reclassifications, net of taxes (36 ) (36 ) —
—
Amounts reclassified into income, net of taxes 18
—
17
1
Balance at December 31, 2017 $ (1,740 ) $ (1,037 ) $ (686 ) $ (17 )
Other comprehensive income before reclassifications, net of taxes 128
128
—
—
Amounts reclassified into income, net of taxes 11
—
9
2
Tax effects reclassified into retained earnings (103 ) —
(99 ) (4 )
Balance at March 31, 2018 $ (1,704 ) $ (909 ) $ (776 ) $ (20 )
Other comprehensive (loss) income before reclassifications, net of taxes (210 ) (214 ) 4
—
Amounts reclassified into income, net of taxes 13
—
12
1
Balance at June 30, 2018 $ (1,902 ) $ (1,123 ) $ (760 ) $ (18 )



(Millions of dollars)	Total			Foreign Currency Translation			Benefit Plans			Cash Flow Hedges
Balance at September 30, 2018	$	(1,909	)	$	(1,162	)	$	(729	)	$	(17	)
Other comprehensive (loss) income before reclassifications, net of taxes	(32		)	(35		)	3			(1		)
Amounts reclassified into income, net of taxes	14			—			13			1
Balance at December 31, 2018	$	(1,927	)	$	(1,197	)	$	(714	)	$	(16	)
Other comprehensive income (loss) before reclassifications, net of taxes	74			76			—			(2		)
Amounts reclassified into income, net of taxes	14			—			13			1
Balance at March 31, 2019	$	(1,839	)	$	(1,121	)	$	(701	)	$	(17	)

The ~~amount~~amounts of foreign currency translation recognized in other comprehensive income during the three and ~~nine~~six months ended ~~June 30,~~March 31, 2020 and 2019 ~~and 2018~~ included net gains (losses) relating to net investment hedges. The amounts recognized in other comprehensive income relating to cash flow hedges ~~as further discussed~~during the three and six months ended March 31, 2020 related to forward starting interest rate swaps. Additional disclosures regarding the Company's derivatives are provided in Note 1312. ~~During the second quarter of 2018, as permitted under U.S. GAAP guidance, the Company reclassified stranded income tax effects on items within~~ ~~Accumulated other comprehensive income (loss)~~ ~~resulting from the enactment of new U.S. tax legislation to~~ ~~Retained earnings.~~ The reclassified tax effects related to prior service credits and net actuarial losses relating to benefit plans, as well as to terminated cash flow hedges. The tax effects relating to these items are generally recognized as such amounts are amortized into earnings.

Note 4 – Earnings per Share

The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) were as follows:


	Three Months Ended June 30,		Nine Months Ended June 30,		Three Months Ended March 31,		Six Months Ended March 31,
	2019	2018	2019	2018	2020	2019	2020	2019
Average common shares outstanding	270,249	267,836	269,719	254,934	272,014	269,882	271,555	269,454
Dilutive share equivalents from share-based plans	4,087	6,089	4,791	5,926	3,023	—	3,618	4,975
Average common and common equivalent shares outstanding – assuming dilution	274,336	273,925	274,510	260,860	275,037	269,882	275,173	274,429

Share equivalents excluded from the diluted shares outstanding calculation because the result would have been antidilutive:
Mandatory convertible preferred stock	11,685	11,685	11,685	11,685	11,685	11,685	11,685	11,685
Share-based plans					—	4,405	—	—

In accordance with the terms of the Company's mandatory convertible preferred stock, on the mandatory conversion date of May 1, 2020, the 2.475 million mandatory convertible preferred shares that were issued in May 2017 in connection with the Company's acquisition of C.R. Bard, Inc. ("Bard") were converted into 11.703 million shares of BD common stock.

Note 5 – Contingencies

Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which the Company is a party. In accordance with U.S. GAAP, the Company establishes accruals to the extent probable future losses are estimable (in the case of environmental matters, without considering possible third-party recoveries). With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below relating to product liability matters, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class. With respect to the civil investigative demand served by the Department of Justice, as discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved.

In view of the uncertainties discussed below, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations and consolidated cash flows.

Product Liability Matters

The Company believes that certain settlements and judgments, as well as legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers, or, in some circumstances, indemnification obligations to the Company from other parties, which if disputed, the Company intends to vigorously contest. Amounts recovered under the Company’s product liability insurance policies or indemnification arrangements may be less than the stated coverage limits or less than otherwise expected and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers or other parties will pay claims or that coverage or indemnity will be otherwise available.

Hernia Product Claims

As of ~~June 30, 2019,~~March 31, 2020, the Company is defending approximately ~~8,795~~16,815 product liability claims involving the Company’s line of hernia repair devices (collectively, the “Hernia Product Claims”). The majority of those claims are currently pending in a coordinated proceeding in Rhode Island State Court, but claims are also pending in other state and/or federal court jurisdictions. In addition, those claims include multiple putative class actions in Canada. Generally, the Hernia Product Claims seek damages for personal injury allegedly resulting from use of the products. From time to time, the Company engages in resolution discussions with plaintiffs’ law firms regarding certain of the Hernia Product Claims, but the Company also intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. Trials are scheduled throughout 2020 in various state and/or federal ~~courts.~~courts, with the first trial currently scheduled for June 2020 in Rhode Island. The Company expects additional trials of Hernia Product Claims to take place over the next 12 months. In August 2018, a new hernia multi-district litigation (“MDL”) was ordered to be established in the Southern District of Ohio. The Company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect

on the Company’s business, results of operations, financial condition and/or liquidity.

Women’s Health Product Claims

As of ~~June 30, 2019,~~March 31, 2020, the Company is defending approximately ~~985~~580 product liability claims involving the Company’s line of pelvic mesh devices. The majority of those claims are currently pending in ~~either the~~various federal ~~MDL in the United States District Court for the Southern District of West Virginia, or~~court jurisdictions, and a coordinated proceeding in New Jersey State Court, but claims are also pending in other state ~~and/or federal~~ court jurisdictions. In addition, those claims include putative class actions filed in the United States. Not included in the figures above are approximately ~~1,010~~1,005 filed and unfiled claims that have been asserted or threatened against the Company but lack sufficient information to determine whether a pelvic mesh device of the Company is actually at issue.

The claims identified above also include products manufactured by both the Company and two subsidiaries of Medtronic plc (as successor in interest to Covidien plc) (“Medtronic”), each a supplier of the Company. Medtronic has an obligation to defend and indemnify the Company with respect to any product defect liability relating to products its subsidiaries had manufactured. ~~As described below, in~~In July 2015, the Company reached an agreement with Medtronic ~~(which was~~in which Medtronic agreed to take responsibility for pursuing settlement of certain of the Women’s Health Product Claims that relate to products distributed by the

Company under supply agreements with Medtronic. In June 2017, the Company amended the agreement with Medtronic to transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on terms similar to the July 2015 agreement, including with respect to the obligation to make payments to Medtronic towards these potential settlements. As of March 31, 2020, the Company has paid Medtronic $141 million towards these potential settlements. The Company also may, in ~~June 2017) regarding certain aspects~~its sole discretion, transfer responsibility for settlement of ~~Medtronic’s indemnification obligation.~~additional Women’s Health Product Claims to Medtronic on similar terms. The agreements do not resolve the dispute between the Company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any. The foregoing lawsuits, unfiled claims, putative class actions, and other claims, together with claims that have settled or are the subject of agreements or agreements in principle to settle, are referred to collectively as the “Women’s Health Product Claims.” The Women’s Health Product Claims generally seek damages for personal injury allegedly resulting from use of the products.

As of ~~June 30, 2019,~~March 31, 2020, the Company has reached agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases totaling approximately ~~15,160~~15,220 of the Women’s Health Product Claims. The Company believes that these Women’s Health Product Claims are not the subject of Medtronic’s indemnification obligation. These settlement agreements and agreements in principle include unfiled and previously unknown claims held by various plaintiffs’ law firms, which are not included in the approximate number of lawsuits set forth in the first paragraph of this section. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. The Company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims, which may include additional inventory settlements.

Starting in 2014 in the MDL, the court entered certain pre-trial orders requiring trial work up and remand of a significant number of Women’s Health Product Claims, including an order entered in the MDL on January 30, 2018, that requires the work up and remand of all remaining unsettled cases (the “WHP Pre-Trial Orders”). The WHP Pre-Trial Orders may result in material additional costs or trial verdicts in future periods in defending Women’s Health Product Claims. Trials are anticipated throughout ~~2019~~2020 in state and federal courts. A trial in the New Jersey coordinated proceeding began in March 2018, and in April 2018 a jury entered a verdict against the Company in the total amount of $68 million ($33 million compensatory; $35 million punitive). The Company is in the process of appealing that verdict. ~~A consolidated trial involving two plaintiffs is scheduled to begin in September 2019 in the New Jersey coordinated proceeding.~~ The Company expects additional trials of Women’s Health Product Claims to take place over the next 12 months, which may potentially include consolidated trials.

In July 2015, as part of the agreement with Medtronic noted above, Medtronic agreed to take responsibility for pursuing settlement of certain of the Women’s Health Product Claims that relate to products distributed by the Company under supply agreements with Medtronic, and the Company has paid Medtronic $121 million towards these potential settlements. In June 2017, the Company amended the agreement with Medtronic to transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on terms similar to the July 2015 agreement, including with respect to the obligation to make payments to Medtronic towards these potential settlements. The Company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms. The agreements do not resolve the dispute between the Company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any.

During the course of engaging in settlement discussions with plaintiffs’ law firms, the Company has learned, and may in future periods learn, additional information regarding these and other unfiled claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company.

Filter Product Claims

As of ~~June 30, 2019,~~March 31, 2020, the Company is defending approximately ~~4,525~~1,785 product liability claims involving the Company’s line of inferior vena cava filters (collectively, the “Filter Product Claims”). The majority of those claims ~~are currently~~were previously pending in an MDL in the United States District Court for the District of Arizona, but those MDL claims either have been, or are in the process of being, remanded to various federal jurisdictions. Filter Product Claims are also pending in ~~other~~various state ~~and/or federal~~ court jurisdictions, including a coordinated proceeding in Arizona State Court. In addition, those claims include putative class actions filed in the United States and Canada. The Filter Product Claims generally seek damages for personal injury allegedly resulting from use of the products. The Company has limited information regarding the nature and quantity of certain of the Filter Product Claims. The Company continues to receive claims and lawsuits and may in future periods learn additional

information regarding other unfiled or unknown claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. On May 31, 2019, the MDL Court ceased accepting direct filings or transfers into the Filter Product Claims MDL and, as noted above, remands for non-settled cases have begun and are expected to ~~begin within~~continue over the next three ~~to six~~ months. ~~The MDL~~Federal and state court trials are scheduled throughout ~~2019 and 2020 in certain state and federal courts.~~2020. As of ~~June 30, 2019,~~March 31, 2020, the Company entered into settlement agreements and/or settlement agreements in principle for approximately ~~4,200~~7,300 cases. On March 30, 2018, a jury in the first MDL trial found the Company liable for negligent failure to warn and entered a verdict in favor of plaintiffs. The jury found the Company was not liable for (a) strict liability design defect; (b) strict liability failure to warn; and (c) negligent design. The Company has appealed that verdict. On June 1, 2018, a jury in the second MDL trial unanimously found in favor of the Company on all claims. On August 17, 2018, the Court entered summary judgment in favor of the Company on all claims in the third MDL trial. On October 5, 2018, a jury in the fourth MDL trial unanimously found in favor of the Company on all claims. The Company expects additional trials of Filter Product Claims may take place over the next 12 months.

In most product liability litigations (like those described above), plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the Company has not yet received and reviewed complete information regarding the plaintiffs and their

medical conditions and, consequently, is unable to fully evaluate the claims. The Company expects that it will receive and review additional information regarding any remaining unsettled product liability matters.

In ~~January 2017,~~connection with the ~~Company reached~~settlement of a prior litigation with certain of the Company's insurance carriers, an agreement ~~to resolve litigation filed in~~with the ~~Southern District of New York by its~~Company's insurance carriers ~~in connection with Women’s Health Product Claims and Filter Product Claims. The agreement requires the insurance carriers~~was reached to reimburse the Company for certain future costs incurred in connection with Filter Product Claims up to an agreed amount. For certain product liability claims or lawsuits, the Company does not maintain or has limited remaining insurance coverage.

Other Legal Matters

Since early 2013, the Company has received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the Company’s products that are the subject of the Hernia Product Claims and the Women’s Health Product Claims. The Company is cooperating with these requests. Although the Company has had, and continues to have, discussions with the State Attorneys General with respect to overall potential resolution of this matter, there can be no assurance that a resolution will be reached or what the terms of any such resolution may be.

In July 2017, a civil investigative demand was served by the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec^® and QuantaFlo^TM devices. The Company is cooperating with these requests. Since it is not feasible to predict the outcome of these matters, the Company cannot give any assurances that the resolution of these matters will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity.

The Company is a potentially responsible party to a number of federal administrative proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as “Superfund,” and similar state laws. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are underway or commencing. For several sites, there are other potentially responsible parties that may be jointly or severally liable to pay all or part of cleanup costs. While it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, the Company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the Company’s business and/or results of operations.

On February 27, 2020, a putative class action captioned Kabak v. Becton, Dickinson and Company, et al., Civ. No. 2:20-cv-02155 (SRC) (CLW), was filed in the U.S. District Court for the District of New Jersey against the Company and certain of its officers. The complaint, which purports to be brought on behalf of all persons (other than defendants) who purchased or otherwise acquired the Company's common stock from November 5, 2019 through February 5, 2020, asserts claims for purported violations of Sections 10 and 20 of the Securities Exchange Act of 1934 and SEC Rule 10b-5 promulgated thereunder, and seeks, among other things, damages and costs. The complaint alleges that defendants concealed material information regarding Alaris^TM infusion pumps, including that (1) certain pumps exhibited software errors, (2) the Company was investing in remediation efforts as opposed to other enhancements and (3) the Company was thus reasonably likely to recall certain pumps and/or experience regulatory delays. These alleged omissions, the complaint asserts, rendered certain public statements about the Company’s business, operations and prospects false or misleading, causing investors to purchase stock at an inflated price. The Company believes these claims are without merit and intends to vigorously defend this action.

On April 27, 2020, three putative stockholders, including the named plaintiff in the Kabak complaint, filed motions to be appointed lead plaintiff and for their counsel to be appointed lead counsel pursuant to the Private Securities Litigation Reform Act of 1995. Those motions remain pending.

The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. The Company believes that it has meritorious defenses to these suits pending against the Company and is engaged in a vigorous defense of each of these matters.

Litigation Reserves

The Company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time.

In the second ~~quarter~~and fourth quarters of fiscal year 2019, the Company recorded a pre-tax ~~charge~~charges to Other operating expense, net, of approximately $331 million and $582 million, respectively, related to certain of the product liability matters discussed above under the heading “Product Liability Matters,”

including the related legal defense costs. The Company recorded ~~this charge~~these charges based on additional information obtained during the ~~quarter, including but not limited to: the allegations~~second and documentation supporting or refuting such allegations; publicly available information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the Company; and the stagefourth quarters of ~~litigation.~~fiscal year 2019.

Accruals for the Company's product liability claims which are ~~specifically~~ discussed above, as well as the related legal defense costs, amounted to approximately ~~$1.9~~$2.3 billion at ~~June 30, 2019~~March 31, 2020 and ~~$2.0~~$2.5 billion at September 30, ~~2018.~~2019. These accruals, which are generally long-term in nature, are largely recorded within Deferred Income Taxes and Other Liabilities on the Company's condensed consolidated balance sheets. As of ~~June 30, 2019~~March 31, 2020 and September 30, ~~2018,~~2019, the Company had ~~$70~~$87 million and ~~$94~~$53 million, respectively, in qualified settlement funds (“QSFs”), subject to certain settlement conditions, for certain product liability matters. Payments to QSFs are recorded as a component of Restricted cash. The Company's expected recoveries related to product liability claims and related legal defense costs were approximately ~~$152~~$117 million and ~~$343~~$150 million at ~~June 30, 2019~~March 31, 2020 and September 30, ~~2018,~~2019, respectively. A substantial amount of these expected recoveries at ~~June 30, 2019~~March 31, 2020 and September 30, ~~2018~~2019 related to the Company’s agreements with Medtronic related to certain Women’s Health Product Claims. During the nine months ended June 30, 2019, Medtronic provided the Company with releases from liability for certain claims that were the subject of the agreement discussed further above. Accordingly, adjustments to reduce accruals for the Company's product liability claims, as well as the balance recorded for expected recoveries related to product liability claims, were recorded during the nine months ended June 30, 2019.

The terms of the Company’s agreements with Medtronic are substantially consistent with the assumptions underlying, and the manner in which, the Company has recorded expected recoveries related to the indemnification obligation. The expected recoveries at ~~June 30, 2019~~March 31, 2020 related to the indemnification obligation are not in dispute with respect to claims that Medtronic settles pursuant to the agreements. As described above, the agreements do not resolve the dispute between the Company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any, and the Company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms.

Note 6 – Revenues

~~As previously discussed~~The Company’s policies for recognizing sales have not changed from those described in ~~Note~~ 2, the ~~Company adopted ASC 606 using the modified retrospective method.~~Company’s 2019 Annual Report on Form 10-K. The Company sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products which are distributed through independent distribution channels and directly by BD through sales representatives. End-users of the Company's products include healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

~~Timing of Revenue Recognition~~

The Company's revenues are primarily recognized when the customer obtains control of the product sold, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. Revenues associated with certain instruments and equipment for which installation is complex, and therefore significantly affects the customer’s ability to use and benefit from the product, are recognized when customer acceptance of these installed products has been confirmed. For certain service arrangements, including extended warranty and software maintenance contracts, revenue is recognized ratably over the contract term. The majority of revenues relating to extended warranty contracts associated with certain instruments and equipment is generally recognized within a few years whereas deferred revenue relating to software maintenance contracts is generally recognized over a longer period.

Measurement of Revenues

The Company acts as the principal in substantially all of its customer arrangements and as such, generally records revenues on a gross basis. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. The Company considers its shipping and handling costs to be costs of contract fulfillment and has made the accounting policy election to record these costs within ~~Selling and administrative expense~~.

Payment terms extended to the Company's customers are based upon commercially reasonable terms for the markets in which the Company's products are sold. Because the Company generally expects to receive payment within one year or less from when control of a product is transferred to the customer, the Company does not generally adjust its revenues for the effects of a financing component. The Company’s estimate of probable credit losses relating to trade receivables is determined based on historical experience and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is ~~uncollectible.~~uncollectable. Such amounts are not material to the Company's consolidated financial results.

The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration ~~include~~includes rebates, sales discounts and sales returns. ~~Because these deductions represent estimates of the related obligations, judgment is required when determining the impact of these revenue~~

deductions on gross revenues for a reporting period. Rebates provided by the Company are based upon prices determined under the Company's agreements with its end-user customers. Additional factors considered in the estimate of the Company's rebate liability include the quantification of inventory that is either in stock at or in transit to the Company's distributors, as well as the estimated lag time between the sale of product and the payment of corresponding rebates. The impact ~~of other forms~~ of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues.

The Company's agreements with customers within certain organizational units including Medication Management Solutions, Diagnostic Systems and Biosciences, contain multiple performance obligations including both products and certain services noted above. The transaction price for these agreements is allocated to each performance obligation based upon its relative standalone selling price. Standalone selling price is the amount at which the Company would sell a promised good or service separately to a customer. The Company generally estimates standalone selling prices using its list prices and a consideration of typical discounts offered to customers.

Effects of Revenue Arrangements on Consolidated Balance ~~Sheet~~Sheets

~~Due to the nature of the majority of the Company's products and services, the Company typically does not incur costs to fulfill a contract in advance of providing the customer with goods or services.~~ Capitalized contract costs associated with the costs to fulfill contracts for certain products in the Medication Management Solutions organizational unit are immaterial to the Company's condensed consolidated balance sheets. The Company's costs to obtain contracts are comprised of sales commissions which are paid to the Company's employees or third party agents. The majority of the sales commissions incurred by the Company relate to revenue that is recognized over a period that is less than one year and as such, the Company has elected a practical expedient provided under ASC 606 to record the majority of its expense associated with sales commissions as it is incurred. Commissions relating to revenues recognized over a period longer than one year are recorded as assets which are amortized over the period over which the revenues underlying the commissions are recognized. Capitalized contract costs related to such commissions are immaterial to the Company's condensed consolidated balance sheets.

~~The Company records contract~~Contract liabilities for unearned revenue that is allocable to performance obligations, such as extended warranty and software maintenance contracts, which are performed over time ~~as discussed further above. These contract liabilities~~ are immaterial to the Company's consolidated financial results. The Company's liability for product warranties provided under its agreements with customers is not material to its condensed consolidated balance sheets.

Remaining Performance Obligations

The Company's obligations relative to service contracts ~~which are further discussed above,~~ and pending installations of equipment, primarily in the Company's Medication Management Solutions unit, represent unsatisfied performance obligations of the Company. The revenues under existing ~~and noncancelable~~ contracts with original expected durations of more than one year, which are attributable to products and/or services that have not yet been installed or provided are estimated to be approximately $1.7 billion at ~~June 30, 2019 and the~~March 31, 2020. The Company expects to recognize the majority of this revenue over the next three years.

Within the Company's Medication Management Solutions, Medication Delivery Solutions, Integrated Diagnostic ~~Systems,~~Solutions, and Biosciences units, some contracts also contain minimum purchase commitments of reagents or other consumables and the future sales of these consumables represent additional unsatisfied performance obligations of the Company. The revenue attributable to the unsatisfied minimum purchase commitment-related performance obligations, for contracts with original expected durations of more than one year, is estimated to be approximately $2.7 billion at March 31, 2020. This revenue will be recognized over the customer relationship ~~period, which usually encompasses the current agreement term and subsequent renewal terms.~~period.

Disaggregation of Revenues

A disaggregation of the Company's revenues by segment, organizational unit and geographic region is provided in Note 7.

Note 7 – Segment Data

The Company's organizational structure is based upon ~~three~~3 principal business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses.

Effective October 1, 2019, Life Sciences joined its former Preanalytical Systems and Diagnostic Systems organizational units to create a new Integrated Diagnostic Solutions organizational unit which focuses on driving growth and innovation around integrated specimen management to diagnostic solutions. The Integrated Diagnostic Solutions organizational unit consists of the following principal product lines:



Organizational Unit		Principal Product Lines
Integrated Diagnostic Solutions		Integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women’s health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays for testing of respiratory infections; microbiology laboratory automation and plated media for clinical and industrial applications.

Revenues by segment, organizational unit and geographical areas for the three and ~~nine-month~~six-month periods are detailed below. The Company has no material intersegment revenues. On December 29, 2017, the Company completed its acquisition of C.R. Bard, Inc. ("Bard"), which is further discussed in Note 9. Bard's operating results were included in the Company’s consolidated results of operations beginning on January 1, 2018 and as such, are not included in the financial results detailed below for the first quarter of the prior-year nine-month period.



	Three Months Ended March 31,
(Millions of dollars)	2020						2019
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions (a)	$	518	$	386	$	904	$	482	$	446	$	928
Medication Management Solutions (a)	449		119		568		499		118		617
Diabetes Care	142		137		278		137		133		270
Pharmaceutical Systems	91		309		400		93		273		366
Total segment revenues	$	1,200	$	951	$	2,151	$	1,211	$	969	$	2,180

Life Sciences
Integrated Diagnostic Solutions
Preanalytical Systems	$	208	$	192	$	400	$	171	$	195	$	366
Diagnostic Systems	206		228		434		180		209		389
Total Integrated Diagnostic Solutions	413		420		833		350		404		755
Biosciences	108		172		280		120		177		297
Total segment revenues	$	522	$	591	$	1,113	$	470	$	582	$	1,052

Interventional
Surgery (b)	$	249	$	63	$	312	$	242	$	66	$	308
Peripheral Intervention (b)	242		157		399		225		162		387
Urology and Critical Care (b)	202		76		279		193		75		268
Total segment revenues	$	693	$	297	$	990	$	659	$	303	$	963

Total Company revenues	$	2,415	$	1,839	$	4,253	$	2,341	$	1,854	$	4,195


(a)	Prior-period amounts reflect the reclassification of U.S. revenues of $2 million associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.


(b)	Prior-period amounts reflect the total reclassifications of $31 million of U.S. revenues and $13 million of international revenues associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit.


	Three Months Ended June 30,												Six Months Ended March 31,
(Millions of dollars)	2019						2018						2020						2019
	United States		International		Total		United States		International		Total		United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions(a)	$	524	$	460	$	984	$	505	$	471	$	977	$	1,038	$	814	$	1,852	$	1,000	$	883	$	1,884
Medication Management Solutions(a)	528		129		658		483		127		610		912		231		1,143		1,007		236		1,242
Diabetes Care	139		136		275		138		138		276		281		266		547		282		261		544
Pharmaceutical Systems	108		286		394		103		279		383		174		525		699		161		485		646
Total segment revenues	$	1,299	$	1,011	$	2,311	$	1,230	$	1,016	$	2,246	$	2,404	$	1,836	$	4,241	$	2,450	$	1,865	$	4,316

Life Sciences
Integrated Diagnostic Solutions
Preanalytical Systems	$	203	$	204	$	407	$	199	$	205	$	404	$	410	$	388	$	798	$	371	$	387	$	758
Diagnostic Systems	155		212		368		151		211		362		390		446		835		355		416		771
Total Integrated Diagnostic Solutions													799		834		1,633		726		803		1,529
Biosciences	117		167		284		126		188		314		260		342		603		228		350		579
Total segment revenues	$	475	$	583	$	1,058	$	476	$	603	$	1,079	$	1,060	$	1,176	$	2,236	$	954	$	1,153	$	2,108

Interventional
Surgery	$	273	$	76	$	349	$	259	$	77	$	336
Peripheral Intervention	195		155		350		195		157		353
Urology and Critical Care	198		85		283		178		87		265
Surgery (b)													$	505	$	133	$	638	$	488	$	130	$	618
Peripheral Intervention (b)													467		327		794		448		321		769
Urology and Critical Care (b)													409		161		570		388		158		545
Total segment revenues	$	666	$	316	$	981	$	632	$	322	$	954	$	1,381	$	621	$	2,002	$	1,323	$	609	$	1,932

Total Company revenues	$	2,440	$	1,910	$	4,350	$	2,338	$	1,941	$	4,278	$	4,845	$	3,634	$	8,479	$	4,728	$	3,628	$	8,355


(a)	Prior-period amounts reflect the reclassification of U.S. revenues of $3 million associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.


(b)	Prior-period amounts reflect the total reclassifications of $63 million of U.S. revenues and $28 million of international revenues associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit.

Nine Months Ended June 30,
(Millions of dollars) 2019 2018
United States International Total United States International Total
Medical
Medication Delivery Solutions $ 1,528
$ 1,344
$ 2,871
$ 1,379
$ 1,298
$ 2,677
Medication Management Solutions 1,531
365
1,896
1,415
364
1,778
Diabetes Care 421
397
819
415
405
820
Pharmaceutical Systems 269
771
1,040
239
755
994
Total segment revenues $ 3,750
$ 2,877
$ 6,626
$ 3,448
$ 2,822
$ 6,270

Life Sciences
Preanalytical Systems $ 574
$ 591
$ 1,165
$ 565
$ 595
$ 1,160
Diagnostic Systems 510
628
1,138
518
634
1,152
Biosciences 345
517
862
350
559
910
Total segment revenues $ 1,430
$ 1,736
$ 3,166
$ 1,433
$ 1,789
$ 3,222

Interventional
Surgery $ 819
$ 223
$ 1,042
$ 687
$ 177
$ 864
Peripheral Intervention 580
449
1,029
393
303
697
Urology and Critical Care 590
253
843
358
171
529
Total segment revenues $ 1,989
$ 925
$ 2,914
$ 1,438
$ 651
$ 2,089

Total Company revenues $ 7,168
$ 5,538
$ 12,706
$ 6,319
$ 5,261
$ 11,581

Segment income for the three and ~~nine-month~~six-month periods was as follows:


	Three Months Ended June 30,						Nine Months Ended June 30,						Three Months Ended March 31,						Six Months Ended March 31,
(Millions of dollars)	2019			2018			2019			2018			2020			2019			2020			2019
Income Before Income Taxes
Medical (a) (b)	$	744		$	732		$	2,008		$	1,943		$	443		$	599		$	1,007		$	1,265
Life Sciences (c)	304			241			902			893			285			293			646			598
Interventional (b) (d)	183			175			623			102
Interventional													213			231			455			441
Total Segment Operating Income	1,230			1,148			3,533			2,938			941			1,123			2,109			2,303
Acquisitions and other restructurings	(90		)	(142		)	(281		)	(600		)	(75		)	(101		)	(161		)	(191		)
Net interest expense	(154		)	(174		)	(490		)	(470		)	(132		)	(153		)	(266		)	(336		)
Other unallocated items ~~(e)~~(d)	(526		)	(184		)	(1,584		)	(1,110		)	(534		)	(866		)	(1,087		)	(1,058		)
Income Before Income Taxes	$	460		$	647		$	1,178		$	759
Total Income Before Income Taxes													$	200		$	3		$	594		$	718

(a)

The ~~amount~~amounts for the ~~nine~~three and six months ended ~~June 30,~~March 31, 2020 include a probable estimate of future costs within the Medication Management Solutions unit associated with remediation efforts related to Alaris^TM infusion pumps of $199 million and $258 million, respectively, which were recorded to Cost of products sold. Based on the course of remediation efforts, it is possible that the estimate of future costs could increase over time.


(b)	The amounts for the three and six-month periods in 2019 included $65 million of estimated remediation costs recorded to Other operating expense, net relating to a recall of a product component, which generally pre-dated the Company's acquisition of CareFusion in fiscal year 2015, within the Medication Management Solutions unit's infusion systems platform.

~~(b)~~(c)

The amounts in 2018 included expense related to the recognition of a $478 million fair value step-up adjustment related to Bard's inventory on the acquisition date. The step-up adjustments recognized by the Medical and Interventional segments for the three ~~months ended June 30, 2018 were $7~~and six-month periods in 2020 include a charge of $39 million ~~and $49 million, respectively, and the adjustments recognized by the Medical and Interventional segments for the nine months ended June 30, 2018 were $60 million and $418 million, respectively.~~


~~(c)~~	~~The amounts in 2018 included charges~~ recorded to ~~write down the carrying value~~Cost of ~~certain intangible and other assets in the Biosciences unit.~~


~~(d)~~	~~The amounts in 2019 included a charge recorded~~ products sold to write down the carrying value of certain intangible assets in the ~~Surgery~~Biosciences unit.

~~(e)~~(d)

Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The ~~amount~~amounts for the ~~nine months ended June 30,~~three and six-month periods in 2019 ~~included~~include a pre-tax charge of $331 million related to certain product liability matters, which is further discussed in Note 5 ~~and also~~. In addition, the amount for the six months ended March 31, 2019 included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately ~~$336~~$335 million, which is further discussed in Note 10. The amounts for the three and nine months ended June 30, 2018 included the pre-tax gain recognized on the Company's sale of its non-controlling interest in Vyaire Medical of approximately $308 million.9.

Note 8 – Benefit Plans

The Company has defined benefit pension plans covering certain employees in the United States and certain international locations. The measurement date used for these plans is September 30.

Net pension cost included the following components for the three and ~~nine~~six months ended ~~June 30:~~March 31:


	Three Months Ended June 30,						Nine Months Ended June 30,						Three Months Ended March 31,						Six Months Ended March 31,
(Millions of dollars)	2019			2018			2019			2018			2020			2019			2020			2019
Service cost	$	33		$	43		$	101		$	107		$	39		$	33		$	79		$	68
Interest cost	26			29			80			70			21			26			43			54
Expected return on plan assets	(44		)	(52		)	(135		)	(125		)	(48		)	(45		)	(97		)	(91		)
Amortization of prior service credit	(3		)	(3		)	(10		)	(10		)	(3		)	(3		)	(7		)	(7		)
Amortization of loss	19			20			58			59			25			19			50			39
Settlements	—			4			—			6
Net pension cost	$	30		$	39		$	93		$	107		$	34		$	31		$	68		$	63

The amounts provided above for amortization of prior service credit and amortization of loss represent the reclassifications of prior service credits and net actuarial losses that were recognized in Accumulated other comprehensive income (loss) in prior periods.

~~As further discussed in Note 2, upon adopting an accounting standard update on October 1, 2018, all~~ All components of the Company’s net periodic pension ~~and postretirement benefit costs,~~cost, aside from service cost, are recorded to Other income (expense), net on its condensed consolidated statements of ~~income, for all periods presented.~~income.

Note 9 – ~~Acquisition~~

~~Bard~~

On December 29, 2017, the Company completed its acquisition of Bard. The operating activities of Bard from the acquisition date through December 31, 2017 were not material to the Company’s consolidated results of operations. As such, Bard's operating results were included in the Company’s consolidated results of operations beginning on January 1, 2018. During the first quarter of fiscal year 2019, the Company finalized its allocation of the fair value of consideration transferred to the individual assets acquired and liabilities assumed in this acquisition, which resulted in no material adjustments to the allocation.

~~Note~~ 10 – Divestiture

~~The~~In October 2018, the Company completed the sale of its Life Sciences segment's Advanced Bioprocessing business in October 2018 pursuant to a definitive agreement that was signed in September 2018. Assets held for sale on the consolidated balance sheet at September 30, 2018, subject to this agreement, were approximately $137 million. Liabilities held for sale under the agreement were immaterial.business. The Company recognized a pre-tax gain on the sale of approximately ~~$336~~$335 million which was recorded as a component of Other operating expense, net~~. The historical financial results for~~in the ~~Advanced Bioprocessing business have not been classified as a discontinued operation.~~first quarter of fiscal year 2019.

Note 1110 – Business Restructuring Charges

The Company incurred restructuring costs during the ~~nine~~six months ended ~~June 30, 2019, largely~~March 31, 2020, in connection with ~~its~~the Company's acquisition of Bard and portfolio rationalization initiatives, which were largely recorded aswithin Acquisitions and other restructurings. Restructuring liability activity for the ~~nine~~six months ended ~~June 30, 2019~~March 31, 2020 was as follows:


(Millions of dollars)	Employee Termination						Other						Total						Employee Termination						Other						Total
	Bard			Other Initiatives			Bard (a)			Other Initiatives			Bard			Other Initiatives			Bard			Other Initiatives			Bard (a)			Other Initiatives			Bard			Other Initiatives
Balance at September 30, 2018	$	33		$	23		$	—		$	4		$	33		$	27
Balance at September 30, 2019																			$	22		$	31		$	1		$	3		$	23		$	34
Charged to expense	12			8			57			22			69			30			6			(2		)	23			14			29			12
Cash payments	(25		)	(21		)	(4		)	(20		)	(29		)	(41		)	(12		)	(23		)	(5		)	(12		)	(17		)	(35		)
Non-cash settlements	—			—			(52		)	(3		)	(52		)	(3		)	—			—			(16		)	(2		)	(16		)	(2		)
Balance at June 30, 2019	$	20		$	10		1			$	3		$	21		$	13
Balance at March 31, 2020																			$	16		$	6		3			$	3		$	19		$	9


(a)	Largely represents the cost associated with certain pre-acquisition equity awards of Bard which, to encourage post-acquisition employee retention, were converted to BD equity awards with substantially the same terms and conditions as were applicable under such Bard awards immediately prior to the acquisition date.

Note 1211 – Intangible Assets

Intangible assets consisted of:


	June 30, 2019				September 30, 2018				March 31, 2020				September 30, 2019
(Millions of dollars)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Amortized intangible assets
Developed technology	$	13,972	$	2,638	$	13,966	$	1,782	$	13,985	$	3,440	$	13,960	$	2,906
Customer relationships	4,610		1,102		4,584		861		4,606		1,345		4,608		1,183
Product rights	115		60		121		58		106		61		110		60
Trademarks	407		97		407		84		407		110		407		102
Patents and other	433		301		397		288		493		315		445		305
Amortized intangible assets	$	19,537	$	4,198	$	19,475	$	3,073	$	19,597	$	5,271	$	19,530	$	4,555
Unamortized intangible assets
Acquired in-process research and development (a)	$	1			$	37			$	46			$	1
Trademarks	2				2				2				2
Unamortized intangible assets	$	3			$	39			$	48			$	3


(a)	The ~~decrease~~increase in the carrying value of assets ~~at June 30, 2019 primarily reflects a write-down recorded~~ in 2020 was attributable to an immaterial acquisition which occurred during the ~~third~~second quarter ~~by the Interventional segment's Surgery unit.~~of fiscal year 2020.

Intangible amortization expense for the three months ended ~~June 30,~~March 31, 2020 and 2019 ~~and 2018~~ was ~~$378~~$347 million and ~~$375~~$376 million, respectively. Intangible amortization expense for the ~~nine~~six months ended ~~June 30,~~March 31, 2020 and 2019 ~~and 2018~~ was ~~$1,132~~$693 million and ~~$879~~$754 million, respectively. ~~The increase in intangible amortization expense for the nine months ended June 30, 2019 was attributable to assets acquired in the Bard transaction, which is further discussed in Note 9.~~

The following is a reconciliation of goodwill by business segment:

(Millions of dollars) Medical Life Sciences Interventional Total
Goodwill as of September 30, 2018 $ 10,054
   $ 775
$ 12,771
   $ 23,600
Divestiture-related adjustments —
3
—
3
Purchase accounting adjustments (a) (15 ) —
(75 ) (90 )
Currency translation (12 ) (3 ) —
(14 )
Goodwill as of June 30, 2019 $ 10,027
   $ 775
$ 12,696
   $ 23,498



(Millions of dollars)	Medical			Life Sciences			Interventional			Total
Goodwill as of September 30, 2019	$	9,989		$	772		$	12,615		$	23,376
Acquisitions (a)	10			58			—			68
Currency translation	(2		)	(1		)	(26		)	(29		)
Goodwill as of March 31, 2020	$	9,997		$	828		$	12,589		$	23,415


(a)	~~The purchase accounting adjustments~~Represents goodwill recognized relative to certain acquisitions which were ~~primarily driven by adjustments to tax-related balances recorded upon~~not material individually or in the ~~finalization of the Bard acquisition allocation within one year of the transaction's closing.~~aggregate.

Note 1312 – Derivative Instruments and Hedging Activities

The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes. The effects these derivative instruments and hedged items have on financial position, financial performance, and cash flows are provided below.

Foreign Currency Risks and Related Strategies

The Company has foreign currency exposures throughout Europe, Greater Asia, Canada and Latin America. Transactional currency exposures that arise from entering into transactions, generally on an intercompany basis, in non-hyperinflationary countries that are denominated in currencies other than the functional currency are mitigated primarily through the use of forward contracts. In order to mitigate foreign currency exposure relating to its investments in certain foreign subsidiaries, the Company has hedged the currency risk associated with those investments with instruments, such as foreign currency-denominated debt, cross-currency swaps and currency exchange contracts, which are designated as net investment hedges.

Hedges of the transactional foreign exchange exposures resulting primarily from intercompany payables and receivables are undesignated hedges. As such, the gains or losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. The net amounts recognized in Other (expense) income, net, during the three and ~~nine~~six months ended ~~June 30,~~March 31, 2020 and 2019 ~~and 2018~~ were immaterial to the Company's consolidated financial results. The total notional amounts of the Company’s outstanding foreign exchange contracts as of ~~June 30, 2019~~March 31, 2020 and September 30, ~~2018~~2019 were ~~$933 million~~$1.2 billion and ~~$3.1~~$2.3 billion, respectively.

Certain of the Company's foreign currency-denominated long-term notes outstanding, which had a total carrying value of ~~$1.8 billion and $3.0~~$1.4 billion as of ~~June 30, 2019~~March 31, 2020 and September 30, ~~2018, respectively,~~2019, were designated as, and were effective as, economic hedges of net investments in certain of the Company's foreign subsidiaries. ~~In connection with the Company's issuance of Euro-denominated notes during the third quarter of fiscal year 2019, the~~The Company has entered into cross-currency swaps, ~~as well as a forward contract,~~all of which ~~were~~are designated and effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. The notional ~~amount~~amounts of the cross-currency swaps ~~was~~were $3.0 billion and $2.3 billion as of ~~June~~March 31, 2020 and September 30, 2019. The forward contract was terminated in the third quarter, in conjunction with the Company's issuance of the Euro-denominated notes. Additional disclosures regarding the Company's issuance of Euro-denominated notes in the third quarter of fiscal year 2019, ~~are provided in Note 15.~~respectively.

Net gains or losses relating to the net investment hedges, which are attributable to changes in the foreign currencies to U.S. dollar spot exchange rates, are recorded as accumulated foreign currency translation in Other comprehensive income (loss). Upon the termination of a net investment hedge, any net gain or loss included in Accumulated other comprehensive income (loss) relative to the investment hedge remains until the foreign subsidiary investment is disposed of or is substantially liquidated.

Net gains (losses) recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges for the three and ~~nine-month~~six-month periods were as follows:


	Three Months Ended June 30,					Nine Months Ended June 30,					Three Months Ended March 31,					Six Months Ended March 31,
(Millions of dollars)	2019			2018		2019			2018		2020		2019			2020		2019
Foreign currency-denominated debt	$	39		$	158	$	81		$	53	$	44	$	(18	)	$	10	$	41
Cross-currency swaps	$	(14	)	$	—	$	(14	)	$	—	$	193	$	—		$	141	$	—
Foreign currency forward contract	$	(9	)	$	—	$	(9	)	$	—

Interest Rate Risks and Related Strategies

The Company’s ~~primary interest rate exposure results from changes in U.S. dollar interest rates. The Company’s~~ policy is to manage interest ~~cost~~rate exposure using a mix of fixed and variable rate debt. The Company periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either fair value or cash flow hedges.

For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates.

The total notional amount of the Company’s outstanding interest rate swaps designated as fair value hedges was $375 million at March 31, 2020 and September 30, 2019. The outstanding swaps represent fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on LIBOR. Changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt. The amounts recorded during the three and six months ended March 31, 2020 and 2019 for changes in the fair value of these hedges were immaterial to the Company's consolidated financial results.

Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are ~~offset by amounts~~ recorded in Other comprehensive income (loss). If interest rate derivatives designated as cash flow hedges are terminated, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is reclassified into earnings over the remaining life of the hedged debt. The net realized loss related to terminated interest rate swaps expected to be reclassified and recorded in Interest expense within the next 12 months is $6 million, net of tax.

The total notional amount of the ~~Company’s~~Company's outstanding forward starting interest rate swaps ~~designated as fair value hedges~~ was ~~$1.2~~$1.5 billion at ~~June 30, 2019~~March 31, 2020 and September 30, ~~2018.~~2019. The ~~outstanding swaps represent fixed-to-floating interest rate swap agreements the~~ Company entered into these contracts in the fourth quarter of fiscal year 2019 to ~~convert the interest payments on certain long-term notes from the fixed rate~~mitigate its exposure to ~~a floating~~ interest rate ~~based on LIBOR. Changes~~risk. The Company recorded after-tax losses of $111 million and $74 million in ~~the fair value of the~~Other comprehensive income (loss) relating to these interest rate ~~swaps offset changes in the fair value of the fixed rate debt. The amounts recorded~~hedges during the three and ~~nine~~six months ended ~~June 30, 2019 and 2018 for changes in the fair value of these hedges were immaterial to the Company's consolidated financial results.~~March 31, 2020, respectively.

Other Risk Exposures

The Company purchases resins, which are oil-based components used in the manufacture of certain products. Significant increases in world oil prices that lead to increases in resin purchase costs could impact future operating results. From time to time, the Company has managed price risks associated with these commodity purchases through commodity derivative forward contracts. The ~~Company's~~Company had 0 outstanding commodity derivative forward contracts at ~~June~~March 31, 2020 and the amount outstanding as of September 30, 2019 ~~were~~was immaterial to the Company's consolidated financial results. ~~The Company had no outstanding commodity derivative forward contracts at September 30, 2018.~~

Financial Statement Effects

The fair values of derivative instruments outstanding at ~~June 30, 2019~~March 31, 2020 and September 30, ~~2018~~2019 were not material to the Company's consolidated balance sheets.

The amounts reclassified from accumulated other comprehensive income relating to cash flow hedges during the three and ~~nine~~six months ended ~~June 30,~~March 31, 2020 and 2019 ~~and 2018~~ were not material to the Company's consolidated financial results.

Note 1413 – Financial Instruments and Fair Value Measurements

The following reconciles cash and equivalents and restricted cash reported within the Company's consolidated balance sheets at ~~June 30, 2019~~March 31, 2020 and September 30, ~~2018~~2019 to the total of these amounts shown on the Company's consolidated statements of cash flows:


(Millions of dollars)	June 30, 2019		September 30, 2018		March 31, 2020		September 30, 2019
Cash and equivalents	$	523	$	1,140	$	2,351	$	536
Restricted cash	71		96		88		54
Cash and equivalents and restricted cash	$	594	$	1,236	$	2,439	$	590

Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase. Restricted cash consists of cash restricted from withdrawal and usage except for certain product liability matters.

The Company’s cash and equivalents ~~includes~~include institutional money market accounts which permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions, which are considered Level 1 inputs in the fair value hierarchy. The fair ~~value~~values of these accounts ~~was immaterial~~were $1.8 billion and $39 million at ~~June~~March 31, 2020 and September 30, 2019, ~~and the fair value of these accounts at September 30, 2018 was $228 million.~~respectively. The Company’s remaining cash and

equivalents, excluding restricted cash, were ~~$523~~$516 million and ~~$913~~$497 million at ~~June 30, 2019~~March 31, 2020 and September 30, ~~2018,~~2019, respectively.

Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments consist of instruments with maturities greater than three months and less than one year.

Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments, which are considered Level 2 inputs in the fair value hierarchy. The fair value of long-term debt was ~~$18.9~~$17.2 billion and ~~$18.8~~$19.2 billion at ~~June 30, 2019~~March 31, 2020 and September 30, ~~2018,~~2019, respectively. The fair value of the current portion of long-term debt was ~~$2.1~~$2.4 billion and ~~$1.9~~$1.3 billion at ~~June 30, 2019~~March 31, 2020 and September 30, ~~2018,~~2019, respectively.

All other instruments measured by the Company at fair value, including derivatives and contingent consideration liabilities, are immaterial to the Company's consolidated balance sheets.

Nonrecurring Fair Value Measurements

In the second quarter of fiscal year 2020, the Company recorded a charge to Cost of products sold of $39 million to write down the carrying value of certain intangible assets in the Biosciences unit. The amount recognized in the second quarter of 2020 was recorded to adjust the carrying amount of assets to the assets' fair values, which were estimated, based upon a market participant's perspective, using Level 3 inputs, as values were estimated using the income approach.

Transfers of trade receivables

Over the normal course of its business activities, the Company transfers certain trade receivable assets to third parties under factoring agreements. Per the terms of these agreements, the Company surrenders control over its trade receivables upon transfer. Accordingly, the Company accounts for the transfers as sales of trade receivables by recognizing an increase to Cash and equivalents and a decrease to Trade receivables, net when proceeds from the transactions are received. The Company’s balance of Trade receivables, net at March 31, 2020 excludes trade receivables of $246 million that have been transferred to third parties under factoring arrangements. The costs incurred by the Company in connection with factoring activities were not material to its consolidated financial results. The Company’s transfers of trade receivables during the six months ended March 31, 2019 were not material to its consolidated financial results.

Note 14 – Debt

While the Company deemed its liquidity sufficient to fund its operations and meet its obligations, the Company has taken steps, as a precautionary measure, to preserve its financial flexibility in light of the uncertainty in the global markets resulting from the COVID-19 pandemic. In March 2020, the Company entered into a 364-day $1.4 billion senior unsecured term loan facility and later in March 2020, this agreement was amended to increase the borrowing capacity available under the facility to $2.0 billion. Borrowings outstanding under the term loan facility were $1.9 billion at March 31, 2020 and these proceeds are included in the Company's balance of Cash and equivalents at March 31, 2020.

In April 2020, the Company entered into a supplement to its existing $2.25 billion senior unsecured revolving credit facility which increased the revolving commitments available to the Company under revolving credit facility by $381 million. As such, the Company's senior unsecured revolving credit facility currently provides borrowings of up to $2.63 billion. Proceeds from this facility are used to fund general corporate needs and borrowings outstanding under the revolving credit facility at March 31, 2020 were $695 million.

Note 15 – ~~Debt~~Leases

~~Second Fiscal Quarter Ended March 31, 2019-Debt Redemption~~

~~In March 2019,~~The Company leases real estate, vehicles and other equipment which are used in the Company’s manufacturing, administrative and research and development activities. The Company identifies a contract that contains a lease as one which conveys a right, either explicitly or implicitly, to control the use of an identified asset in exchange for consideration. The Company’s lease arrangements are generally classified as operating leases. These arrangements have remaining terms ranging from less than one year to approximately 25 years and the weighted-average remaining lease term of the Company’s leases is approximately 7.5 years. An option to renew or terminate the current term of a lease arrangement is included in the lease term if the Company ~~redeemed an aggregate principal amount~~is reasonably certain to exercise that option.

The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of ~~$250 million of~~12 months or less, on its ~~outstanding floating rate senior unsecured U.S. notes due December 29, 2020. Based~~consolidated balance sheet. For the longer-term lease arrangements that are recognized on the Company’s consolidated balance sheet, the right-of-use asset and lease liability is initially measured at the commencement date based upon the ~~$249 million carrying~~present value of the ~~notes redeemed~~lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the ~~$250 million~~arrangement. The costs associated with the Company’s short-term leases, as well as variable costs relating to the Company’s lease arrangements, are not material to its consolidated financial results.

The implicit interest rates of the Company’s lease arrangements are generally not readily determinable and as such, the Company ~~paid~~applies an incremental borrowing rate, which is established based upon the information available at the lease commencement date, to ~~redeem~~determine the ~~aggregate principal amount~~present value of lease payments due under an arrangement. The weighted-average incremental borrowing rate that has been applied to measure the ~~notes, the Company~~Company’s lease liabilities is 2.3%.

The Company’s lease costs recorded ~~a loss on this debt extinguishment transaction~~ in ~~the second quarter of fiscal year 2019 of $1 million as~~ ~~Other (expense) income, net, on~~ its consolidated statements of ~~income.~~

~~Third Fiscal Quarter Ended June 30, 2019-Debt-Related Transactions~~

~~In June 2019, Becton Dickinson Euro Finance S.à r.l., a private limited liability company (société à responsabilité limitée), which is an indirect, wholly-owned finance subsidiary~~income for the three and six months ended March 31, 2020 were $32 million and $65 million, respectively. Cash payments arising from the Company’s lease arrangements are reflected on its condensed consolidated statement of ~~the Company, issued Euro-denominated debt consisting of 600 million Euros ($672 million) of 0.174% notes due June 4, 2021, 800 million Euros ($896 million) of 0.632% notes due June 4, 2023,~~cash flows as outflows used for operating activities. The right-of-use assets and 600 million Euros ($672 million) of 1.208% notes due June 4, 2026. The notes are fully and unconditionally guaranteed on a senior unsecured basis by the Company. No other of the Company's subsidiaries provide any guarantees with respect to these notes. The indenture covenants include a limitation on liens and a restriction on sale and leasebacks, change of control and consolidation, merger and sale of assets covenants. These covenants are subject to a number of exceptions, limitations and qualifications. The indenture does not restrict the Company, Becton Dickinson Euro Finance S.à r.l., or any other of the Company's subsidiaries from incurring additional debt or otherlease liabilities ~~including additional senior debt. Additionally, the indenture does not restrict Becton Dickinson Euro Finance S.à r.l. and the Company from granting security interests over its assets.~~

The Company used the net proceeds from this long-term debt offering, together with cash on hand, to repay all the 1.000 billion Euros ($1.120 billion) of principal outstanding on 0.368% notes due June 6, 2019, as well as to fund the Company's repurchase of certain of its long-term senior notes outstanding. Under this cash tender offer, the Company repurchased the following aggregate principal amounts of its long-term debt at an aggregate market price of $1.169 billion:

Interest Rate and Maturity
Aggregate
Principal Amount
(Millions of dollars)
3.700% Notes due June 6, 2027 $ 675
5.000% Notes due November 12, 2040 175
4.875% Notes due May 15, 2044 75
4.685% Notes due December 15, 2044 175
Total notes purchased $ 1,100

~~The carrying value of these long-term notes was $1.112 billion, and the Company~~ recognized ~~a loss on this debt extinguishment of $57 million, which was recorded in June 2019 as~~ ~~Other (expense) income, net~~, on the Company’s condensed consolidated ~~statements~~balance sheet as of ~~income.~~March 31, 2020 were as follows:



(Millions of dollars)	March 31, 2020
Right-of-use assets recorded in Other Assets	$	427
Current lease liabilities recorded in Payables, accrued expenses and other current liabilities	$	103
Non-current lease liabilities recorded in Deferred Income Taxes and Other Liabilities	$	345

The Company’s payments due under its operating leases are as follows:



(Millions of dollars)
Remaining for 2020	$	58
2021	102
2022	83
2023	55
2024	36
Thereafter	164
Total payments due	499
Less: imputed interest	50
Total	$	448

~~Note~~ 16 ~~– Income Taxes~~

~~New U.S. tax legislation, which is commonly referred to~~The Company’s future minimum rental commitments on non-cancelable leases at September 30, 2019, as the Tax Cuts and Jobs Act (the "Act"), was enacted on December 22, 2017. The Act subjects a U.S. shareholder to tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The Company has elected to account for its GILTI tax due as a period expensedisclosed in the ~~year the tax is incurred.~~Company’s 2019 Annual Report on Form 10-K, were as follows:



(Millions of dollars)
2020	$	122
2021	103
2022	83
2023	57
2024	56
Thereafter	123
Total	$	546

Upon completing its accounting for the tax effects of the Act during fiscal year 2019, the Company recognized a net charge of $10 million, which is reflected in the Company's consolidated statement of income within ~~Income tax provision, to adjustits one-time transition tax liability for all of its foreign subsidiaries. Also during fiscal year 2019, the Company recorded a $67 million decrease to~~ ~~Income tax provision~~ ~~to adjust the Company's reevaluation of the permanent reinvestment assertion regarding foreign earnings, as well as an increase to~~ ~~Income tax provision~~ ~~of $2 million relating to the Company's re-measurement of deferred tax balances.~~

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following commentary should be read in conjunction with the condensed consolidated financial statements and accompanying notes presented in this report. Within the tables presented throughout this discussion, certain columns may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

Company Overview

Becton, Dickinson and Company (“BD”) is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company's organizational structure is based upon three principal business segments, BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”).

BD’s products are manufactured and sold worldwide. Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives. We organize our operations outside the United States as follows: Europe; EMA (which includes the Commonwealth of Independent States, the Middle East and Africa); Greater Asia (which includes ~~Japan~~countries in East Asia, South Asia, Southeast Asia and ~~Asia Pacific)~~the Oceania region); Latin America (which includes Mexico, Central America, the Caribbean, and South America); and Canada. We continue to pursue growth opportunities in emerging markets, which include the following geographic regions: Eastern Europe, the Middle East, Africa, Latin America and certain countries within ~~Asia Pacific.~~Greater Asia. We are primarily focused on certain countries whose healthcare systems are expanding.

Recent Developments

A novel strain of coronavirus (“COVID-19”) was officially declared a pandemic by the World Health Organization ("WHO") in March 2020. In efforts to slow the spread of COVID-19, governments around the world have issued travel restrictions as well as recommendations or mandates to avoid large gatherings or to self-quarantine. Such measures have led to a sudden and significant decline in economic activity within a number of countries worldwide. The COVID-19 pandemic has resulted in a decline in elective procedures which has unfavorably impacted our results of operations for the three months ended March 31, 2020. While certain of our organizational units realized positive benefits to revenues from the pandemic for the second quarter, the estimated net impact on total consolidated revenues was an unfavorable impact of $56 million.

We are deploying our capabilities, expertise and scale to address critical health needs related to COVID-19. A molecular test for the detection of COVID-19 for clinical laboratories is currently available and we are also currently developing a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19. We have been adhering to guidance provided by the WHO, as well as by health officials in various countries affected by the COVID-19 pandemic, to protect the health and safety of BD employees while ensuring continued availability of BD’s critical medical devices and technologies at this unprecedented time. We have enacted business continuity plans in order to minimize the risk of disruption to our operations and supply chain, and to date, we have not experienced any significant disruption. We have been working closely with governmental officials in an effort to keep our manufacturing facilities (and those of our suppliers) open due to the essential nature of our products.

We continue to generate operating cash flows that are sufficient to meet our short-term liquidity needs. We have taken steps, as a precautionary measure, to preserve our financial flexibility in light of uncertainty in the global markets resulting from the COVID-19 pandemic. Such measures included entering into a $2.0 billion term loan agreement and increasing the commitments available under our revolving credit facility by $381 million, as is further discussed in Note 14 in the Notes to Condensed Consolidated Financial Statements. We believe that given our debt ratings and our capital allocation strategy, we would have access to additional short-term and long-term capital should the need arise. We have not observed any impairments of our assets due to the COVID-19 pandemic and the decline in global economic activity.

We have enacted certain cost containment measures to mitigate the unfavorable impact of the COVID-19 pandemic to our future results of operations. Such actions have included travel restrictions, temporary reductions in executive compensation, a temporary suspension of matching contributions to certain voluntary defined contribution and other benefit plans, as well as temporary work reductions for certain manufacturing teams.

Our business is experiencing weakened demand for our products as a result of a significant decline in medical procedures due to government restrictions and healthcare priorities, particularly with respect to hernia and other elective procedures. We are also seeing delays in instrument placements relating to our medical management solutions, including Pyxis™, as well as decreased non-COVID-19 diagnostic testing and specimen collections, which is being partially offset by higher demand for COVID-19 testing. There has also been a decrease in research activity due to laboratory closures and reduced clinical testing.

Accordingly, our future operating performance, particularly in the short-term, will be subject to volatility. The ultimate impact of the COVID-19 pandemic on our business, results of operations, financial condition and cash flows is dependent on future developments, which are uncertain at this time, including:

The timing and extent of recovery in the global demand for our products, particularly those sold by our Surgery and Peripheral Interventional units which are used in elective medical procedures;

The pace at which hospitals resume patient care that is not related to the COVID-19 pandemic;

The progress of development for our point-of-care test, which was previously discussed above, and the degree to which COVID-19 testing solutions are made available and utilized by governments;

The timing of when research performed by research laboratories and institutions will resume to normal operations; and

The degree of pressure that the weaker macroeconomic environment will put on future healthcare utilization.

Further discussion regarding the impacts of the COVID-19 pandemic on our results for the three months ended March 31, 2020 is provided below.

Overview of Financial Results and Financial Condition

For the three months ended ~~June 30, 2019,~~March 31, 2020, worldwide revenues of ~~$4.350~~$4.253 billion increased ~~1.7%~~1.4% from the prior-year period which reflected volume growth of approximately 6%2.3%, an unfavorable impact from foreign currency translation of approximately ~~3.0%~~1.0% and a favorable impact from pricing ~~pressures~~ of approximately ~~0.4%~~0.1%. We estimate that the COVID-19 pandemic reduced volume growth in the second quarter by approximately 1.4%. Volume growth in the second quarter of fiscal year 2020 reflected the following:

Medical segment revenues in the second quarter reflected strong growth in the Pharmaceutical Systems. Revenues ~~for~~in the ~~three months ended June 30, 2019 also reflected an unfavorable impact of approximately 1% attributable~~Diabetes Care unit benefited from COVID-19 due to increased orders from retailers and distributors in the ~~Biosciences unit's divestiture of its Advanced Bioprocessing business at~~United States. Medical segment revenues in the ~~end of October 2018,~~second quarter were unfavorably impacted by declines in the Medication Management Solutions and Medication Delivery Solutions units, as is further discussed ~~in Note 10 in the Notes to Condensed Consolidated Financial Statements. Volume growth in the third quarter of fiscal year 2019 was as follows:~~

~~Medical segment growth in the third quarter was driven by the segment's Medication Management Solutions, Medication Delivery Solutions and Pharmaceutical Systems units.~~below.

Life Sciences segment ~~growth~~revenues in the ~~third~~second quarter reflected growth in ~~all~~the Integrated Diagnostic Solutions unit that was partially offset by declines in the Biosciences unit due to the COVID-19 pandemic and an unfavorable comparison to the prior-year period due to the timing of ~~the segment's units.~~licensing revenues.

Interventional segment ~~growth~~revenues in the ~~third~~second quarter reflected sales growth in all ~~units, particularly in the Urology and Critical Care unit as well as~~units. Revenues in the Surgery ~~unit.~~and Peripheral Intervention units were negatively impacted by the deferral of elective medical procedures as a result of the COVID-19 pandemic.

Second quarter Medical segment revenues were unfavorably impacted by the Medication Management Solutions unit's delay of shipments of Alaris^TM infusion pumps pending compliance with certain 510(k) filing requirements of the U.S. Food and Drug Administration ("FDA"), as previously reported. While we continue to make progress on our regulatory filing related to the Alaris^TM infusion pumps, due to the COVID-19 pandemic and other factors, we no longer expect to submit the 510(k) to the FDA in the fourth quarter of fiscal year 2020.

We continue to invest in research and development, geographic expansion, and new product ~~market~~development programs to drive further revenue and profit growth. Our ability to sustain our long-term growth will depend on a number of factors, including our ability to expand our core business (including geographical expansion), develop innovative new products, and continue to improve operating efficiency and organizational effectiveness. While the economic ~~environment~~environments for the healthcare industry and healthcare utilization in the United States isand Europe have been generally stable, destabilization inresulting from the ~~future could~~COVID-19 pandemic or other factors has adversely ~~impact~~impacted our businesses. ~~Additionally, macroeconomic challenges in Europe~~Our businesses will continue to ~~constrain healthcare utilization, although we currently view~~be impacted by the ~~environment as stable.~~COVID-19 pandemic throughout its duration and while government measures implemented in response to the pandemic continue to be in place. In emerging markets, the Company’s growth is dependent primarily on government funding for healthcare systems. In addition, pricing pressure exists globally which could adversely impact our businesses.

Cash flows from operating activities were ~~$1.959~~$1.196 billion in the first ~~nine~~six months of fiscal year ~~2019.~~2020. At ~~June 30, 2019,~~March 31, 2020, we had ~~$606 million~~$2.445 billion in cash and equivalents and short-term investments, including restricted cash. We continued to return value to our shareholders in the form of dividends. During the first ~~nine~~six months of fiscal year ~~2019,~~2020, we paid cash dividends of ~~$737~~$505 million, including ~~$624~~$430 million paid to common shareholders and ~~$114~~$76 million paid to preferred shareholders.

Each reporting period, we face currency exposure that arises from translating the results of our worldwide operations to the U.S. dollar at exchange rates that fluctuate from the beginning of such period. A stronger U.S. dollar, compared to the prior-year period, resulted in an unfavorable foreign currency translation impact to our revenues ~~and earnings~~ during the ~~third~~second quarter of fiscal year ~~2019.~~2020. We evaluate our results of operations on both a reported and a foreign currency-neutral basis, which excludes the impact of fluctuations in foreign currency exchange rates. As exchange rates are an important factor in understanding ~~period-to-period~~period-to-

period comparisons, we believe the presentation of results on a foreign currency-neutral basis in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. Foreign currency-neutral ("FXN") information compares results between periods as if exchange rates had remained constant period-over-period. We use results on a foreign currency-neutral basis as one measure to evaluate

our performance. We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior-period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. These results should be considered in addition to, not as a substitute for, results reported in accordance with U.S. generally accepted accounting principles ("GAAP"). Results on a foreign currency-neutral basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP.

Results of Operations

Medical Segment

The following summarizes ~~third~~second quarter Medical revenues by organizational unit:


	Three months ended June 30,										Three months ended March 31,
(Millions of dollars)	2019		2018		Total Change		Estimated FX Impact		FXN Change		2020		2019		Total Change		Estimated FX Impact		FXN Change
Medication Delivery Solutions(a)	$	984	$	977	0.8	%	(3.3	)%	4.1	%	$	904	$	928	(2.5	)%	(1.2	)%	(1.3	)%
Medication Management Solutions(a)	658		610		7.7	%	(1.5	)%	9.2	%	568		617		(7.9	)%	(0.4	)%	(7.5	)%
Diabetes Care	275		276		(0.4	)%	(3.3	)%	2.9	%	278		270		2.9	%	(1.3	)%	4.2	%
Pharmaceutical Systems	394		383		3.1	%	(4.7	)%	7.8	%	400		366		9.4	%	(2.0	)%	11.4	%
Total Medical Revenues	$	2,311	$	2,246	2.9	%	(3.1	)%	6.0	%	$	2,151	$	2,180	(1.4	)%	(1.1	)%	(0.3	)%


(a)	The presentation of prior-period amounts reflects the reclassification of $2 million associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.

~~Third~~Second quarter Medical segment revenues reflected ~~sales~~strong growth ~~attributable to~~in the Pharmaceutical Systems and Diabetes Care units that was offset by declines in the Medication Management Solutions and Medication Delivery Solutions units. As anticipated, the Medication Management Solutions unit's ~~installations~~revenues were unfavorably impacted by the delay of shipments of Alaris^TMinfusion ~~systems and sales of disposables. Revenues in~~pumps, as previously discussed above. Also as expected, the Medication Delivery Solutions unit's second quarter revenues in China were unfavorably impacted by a new volume-based procurement process which has been adopted by several of China's provinces. The Medication Delivery Solutions unit's second quarter revenues also reflected an unfavorable impact relating to the COVID-19 pandemic, most notably in China, where healthcare utilization declined significantly. The Diabetes Care unit ~~reflected growth in global sales of vascular access devices. The Pharmaceutical Systems unit's third~~realized a benefit to second quarter ~~revenue growth was driven by sales of self-injection systems. Strength~~revenues from COVID-19 due to increased orders from retailers and distributors in the ~~Diabetes Care unit's sales of pen needles in emerging markets was partially offset by weaker U.S. sales in the current-year period compared with sales in the prior-year period.~~United States.

Medical segment total revenues for the ~~nine-month period are below. Revenues in the current-year~~six-month period were favorably impacted by the inclusion of revenues, resulting from our acquisition of C.R. Bard, Inc. ("Bard") in December 2017, associated with certain Bard products within the Medication Delivery Solutions unit in the first quarter of fiscal year 2019 but not in the first quarter of the prior-year period as ~~operating activities of the acquired business were not included in our consolidated results of operations until January 1, 2018.~~follows:


	Nine months ended June 30,										Six months ended March 31,
(Millions of dollars)	2019		2018		Total Change		Estimated FX Impact		FXN Change		2020		2019		Total Change		Estimated FX Impact		FXN Change
Total Medical Revenues	$	6,626	$	6,270	5.7	%	(2.6	)%	8.3	%	$	4,241	$	4,316	(1.7	)%	(1.1	)%	(0.6	)%

Medical segment ~~operating~~ income for the three and ~~nine-month~~six-month periods is provided below. ~~Operating income in the current year's nine-month period reflects the inclusion of results associated with certain Bard products in the first quarter of 2019, as noted above.~~

Three months ended June 30, Nine months ended June 30,
(Millions of dollars) 2019 2018 2019 2018
Medical segment operating income $ 744
$ 732
$ 2,008
$ 1,943

Segment operating income as % of Medical revenues 32.2 % 32.6 % 30.3 % 31.0 %



	Three months ended March 31,						Six months ended March 31,
(Millions of dollars)	2020			2019			2020			2019
Medical segment income	$	443		$	599		$	1,007		$	1,265

Segment income as % of Medical revenues	20.6		%	27.5		%	23.8		%	29.3		%

The Medical segment's ~~operating~~ income in the ~~third~~second quarter was driven by its performance with respect to gross profit margin and operating ~~expenses.~~

~~Gross profit margin was lower~~expenses as discussed in the third quarter of 2019 as compared with the third quarter of 2018 primarily due to unfavorable foreign currency translation, unfavorable product mix, pricing pressures and higher raw material costs. These unfavorable impacts to the Medical segment's gross margin were partially offset by lower manufacturing costs resulting from continuous improvement projects which enhanced the efficiency of our operations, as well as the unfavorable prior-year impact of recognizing a fair value step-up adjustment relating to Bard's inventory on the acquisition date.greater detail below:

•

Gross profit margin was lower in the second quarter of 2020 as compared with the second quarter of 2019 which primarily reflected a charge to record a probable estimate of future costs associated with incremental remediation efforts relating to Alaris^TM infusion pumps, as further discussed below. This unfavorable impact to the Medical segment's gross margin was partially offset by lower manufacturing costs resulting from continuous improvement projects which enhanced the efficiency of our operations and favorable foreign currency translation.

Selling and administrative expense as a percentage of revenues was slightly lower in the ~~third~~second quarter of ~~2019 as~~2020 compared with the ~~prior-year period~~second quarter of 2019 primarily due to lower ~~selling expenses.~~expenses resulting from recently enacted cost containment measures.

Research and development expense as a percentage of revenues was ~~lower~~higher in the ~~third~~second quarter of 2020 compared with the second quarter of 2019 ~~as compared with the third quarter of 2018~~primarily due to ~~recent completion of projects and~~ the timing of project spending.


•	The Medical segment's income in the second quarter of 2019 additionally reflected the estimated cumulative costs of a product recall of $65 million recorded within Other operating expense, net. The recall related to a product component, which generally pre-dated our acquisition of CareFusion in fiscal year 2015, within the Medication Management Solutions unit's infusion systems platform.

Life Sciences Segment

The following summarizes ~~third~~second quarter Life Sciences revenues by organizational unit:


	Three months ended June 30,										Three months ended March 31,
(Millions of dollars)	2019		2018		Total Change		Estimated FX Impact		FXN Change		2020		2019		Total Change		Estimated FX Impact		FXN Change
Integrated Diagnostic Solutions (a)
Preanalytical Systems	$	407	$	404	0.7	%	(4.0	)%	4.7	%	$	400	$	366	9.3	%	(1.5	)%	10.8	%
Diagnostic Systems	368		362		1.7	%	(3.9	)%	5.6	%	434		389		11.5	%	(1.4	)%	12.9	%
Total Integrated Diagnostic Solutions											833		755		10.4	%	(1.5	)%	11.9	%
Biosciences	284		314		(9.6	)%	(2.9	)%	(6.7	)%	280		297		(5.9	)%	(0.9	)%	(5.0	)%
Total Life Sciences Revenues	$	1,058	$	1,079	(2.0	)%	(3.7	)%	1.7	%	$	1,113	$	1,052	5.8	%	(1.3	)%	7.1	%


(a)	Effective October 1, 2019, the Preanalytical Systems and Diagnostic Systems units were joined to create the new Integrated Diagnostic Solutions unit. Additional disclosures regarding this change are provided in Note 7 in the Notes to Condensed Consolidated Financial Statements.

The Life Sciences segment's revenues in the ~~third~~second quarter reflected ~~continued strength~~strong sales in ~~sales of~~ the Integrated Diagnostic ~~Systems unit's~~ BD~~MAX~~^TM ~~molecular platform~~Solutions unit which were driven by a more severe influenza season in the current year as ~~well as growth in sales of core microbiology products. The Preanalytical Systems unit's third quarter revenues reflected growth in sales of core products in emerging markets. Third~~compared with the prior year's season. Second quarter revenues in the Biosciences unit primarily reflected ~~growth~~a decline in ~~research~~instrument installations and reagent sales as a result of the COVID-19 pandemic, as well as ~~growth in U.S. research instrument sales, but were unfavorably impacted by the divestiture of the Advanced Bioprocessing business, as previously discussed. The Biosciences unit's results for~~an unfavorable comparison to the prior-year period ~~included~~due to the timing of licensing revenues ~~associated with the Advanced Bioprocessing business of $35 million.~~and tenders in emerging markets.

Life Sciences segment total revenues for the ~~nine-month~~six-month period were as follows:


	Nine months ended June 30,										Six months ended March 31,
(Millions of dollars)	2019		2018		Total Change		Estimated FX Impact		FXN Change		2020		2019		Total Change		Estimated FX Impact		FXN Change
Total Life Sciences Revenues	$	3,166	$	3,222	(1.7	)%	(3.0	)%	1.3	%	$	2,236	$	2,108	6.1	%	(1.2	)%	7.3	%

Life Sciences segment ~~operating~~ income for the three and ~~nine-month~~six-month periods was as follows:

Three months ended June 30, Nine months ended June 30,
(Millions of dollars) 2019 2018 2019 2018
Life Sciences segment operating income $ 304
$ 241
$ 902
$ 893

Segment operating income as % of Life Sciences revenues 28.7 % 22.4 % 28.5 % 27.7 %



	Three months ended March 31,						Six months ended March 31,
(Millions of dollars)	2020			2019			2020			2019
Life Sciences segment income	$	285		$	293		$	646		$	598

Segment income as % of Life Sciences revenues	25.6		%	27.8		%	28.9		%	28.4		%

The Life Sciences segment's ~~operating~~ income in the ~~third~~second quarter was driven by its performance with respect to gross profit margin and operating ~~expenses.~~expenses as discussed in greater detail below:

Gross profit margin in the third quarter of fiscal year 2019 was higher compared with the third quarter of 2018 primarily due to the unfavorable prior-year impact of the Biosciences unit's write-down of certain intangible and other assets. Gross margin in the ~~third~~second quarter of 2020 was lower compared with the second quarter of 2019 ~~was also favorably impacted by lower manufacturing costs resulting from continuous improvement projects~~ which ~~enhanced~~primarily reflected a $39 million charge to write down the ~~efficiency~~carrying value of ~~our operations.~~certain intangible assets in the Biosciences unit, as well as unfavorable product mix and increased tariffs. These ~~favorable~~unfavorable impacts to the Life Sciences segment's gross margin were partially offset by ~~unfavorable foreign currency translation and unfavorable product mix.~~

Selling and administrative expense as a percentage of revenues in the third quarter of 2019 was lower compared with the prior-year period primarily due to the timing of marketing program spending, offset by unfavorable foreign currency translation.

Research and development expense as a percentage of revenues was lower in the third quarter of 2019 as compared with the third quarter of 2018 primarily due to the Biosciences unit's recognition of write-downs in the prior-year period and also due to the timing of project spending.

~~Interventional Segment~~

~~The following summarizes third quarter Interventional revenues by organizational unit:~~

Three months ended June 30,
(Millions of dollars) 2019 2018
Total
Change

Estimated
FX
Impact
FXN Change
Surgery $ 349
$ 336
3.9 % (1.5 )% 5.4 %
Peripheral Intervention 350
353
(0.8 )% (3.1 )% 2.3 %
Urology and Critical Care 283
265
6.5 % (2.0 )% 8.5 %
Total Interventional Revenues $ 981
$ 954
2.9 % (2.3 )% 5.2 %

The Interventional segment's revenues in the third quarter reflected growth in the Urology and Critical Care unit's sales of acute urology products and sales by the unit's home care and targeted temperature management businesses. Third quarter revenues in the Surgery unit reflected growth in sales of the unit's biosurgery and infection prevention products. The Peripheral Intervention unit's third quarter revenues reflected growth in emerging market sales. This growth was partially offset by an unfavorable impact related to a letter issued in March 2019 by the U.S. Food and Drug Administration ("FDA") to healthcare professionals regarding the use of paclitaxel-coated devices in the treatment of peripheral artery disease, which impacted sales of our drug-coated balloon products.

Interventional segment total revenues for the nine-month period are provided below. Revenues in the current-year period were favorably impacted by the inclusion of revenues associated with Bard's products in the segment's results for the first quarter of fiscal year 2019, as further discussed above.

Nine months ended June 30,
(Millions of dollars) 2019 2018 Total
Change Estimated
FX
Impact FXN Change
Total Interventional Revenues $ 2,914
$ 2,089
39.5 % (2.2 )% 41.7 %

Interventional segment operating income for the three and nine-month periods is provided below. Operating income in the current year's nine-month period reflects the inclusion of Bard results in the first quarter of 2019, as further discussed above.

Three months ended June 30, Nine months ended June 30,
(Millions of dollars) 2019 2018 2019 2018
Interventional segment operating income $ 183
$ 175
$ 623
$ 102

Segment operating income as % of Interventional revenues 18.6 % 18.3 % 21.4 % 4.9 %

~~The Interventional segment's operating income in the third quarter was driven by its performance with respect to gross profit margin and operating expenses.~~

Gross profit margin was higher in the third quarter of 2019 as compared with the third quarter of 2018 primarily due to the unfavorable prior-year impact of recognizing a fair value step-up adjustment relating to Bard's inventory on the acquisition datefavorable impacts from pricing and lower manufacturing costs resulting from continuous improvement projects which enhanced the efficiency of our ~~operations, and synergy initiatives. These favorable impacts to the Interventional segment's gross margin were partially offset by unfavorable foreign currency translation and unfavorable product mix.~~operations.

Selling and administrative expense as a percentage of revenues in the ~~third~~second quarter of ~~2019~~2020 was ~~relatively flat~~lower compared with the prior-year ~~period.~~period primarily due to expense synergies realized from the combination of the Preanalytical Systems and Diagnostic Systems units, as noted above, and lower expenses resulting from recently enacted cost containment measures.

Research and development expense as a percentage of revenues was ~~higher~~lower in the ~~third~~second quarter of 2020 compared with the second quarter of 2019 primarily due to the timing of project spending.

Interventional Segment

The following summarizes second quarter Interventional revenues by organizational unit:



	Three months ended March 31,
(Millions of dollars)	2020		2019		Total Change		Estimated FX Impact		FXN Change
Surgery (a)	$	312	$	308	1.4	%	(0.3	)%	1.7	%
Peripheral Intervention (a)	399		387		3.1	%	(0.9	)%	4.0	%
Urology and Critical Care (a)	279		268		4.1	%	(0.1	)%	4.2	%
Total Interventional Revenues	$	990	$	963	2.8	%	(0.5	)%	3.3	%


(a)	The presentation of prior-period amounts reflects the total reclassifications of $45 million associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit.

Second quarter revenues in the Interventional segment reflected strong sales of products in the Peripheral Intervention and Urology and Critical Care units. Revenue growth in the Peripheral Intervention unit was partially offset by lower sales of our drug-coated balloon products as compared to the prior-year period following the previously reported FDA's March 2019 letter to healthcare professionals regarding the use of paclitaxel-coated devices. The extent and duration of the impact from the FDA letter on the Peripheral Intervention unit’s future revenues is difficult to predict. Second quarter revenues within the Surgery and Peripheral Intervention units were negatively impacted by decreased demand associated with the deferral of elective medical procedures as a result of the COVID-19 pandemic.

Interventional segment total revenues for the six-month period were as follows:



	Six months ended March 31,
(Millions of dollars)	2020		2019		Total Change		Estimated FX Impact		FXN Change
Total Interventional Revenues	$	2,002	$	1,932	3.6	%	(0.5	)%	4.1	%

Interventional segment income for the three and six-month periods is provided below.



	Three months ended March 31,						Six months ended March 31,
(Millions of dollars)	2020			2019			2020			2019
Interventional segment income	$	213		$	231		$	455		$	441

Segment income as % of Interventional revenues	21.5		%	24.0		%	22.7		%	22.8		%

The Interventional segment's income in the second quarter was driven by its performance with respect to gross profit margin and operating expenses as discussed in greater detail below:

Gross profit margin was lower in the second quarter of 2020 as compared with the ~~third~~second quarter of ~~2018~~2019 primarily due to the ~~Surgery unit's recognition~~amortization of recently acquired intangible assets, which was partially offset by favorable product mix and favorable foreign currency translation.

Selling and administrative expense as a percentage of revenues in the second quarter of 2020 was lower compared with the prior-year period primarily due to lower expenses resulting from recently enacted cost containment measures.

Research and development expense as a percentage of revenues was lower in the second quarter of 2020 compared with the second quarter of 2019 primarily due to the timing of project spending.

The Interventional segment's lower income in the second quarter of 2020 additionally reflected the expiration in 2019 of a ~~write-down~~royalty income stream acquired in the ~~current-year period, as further discussed below.~~

C.R. Bard, Inc. ("Bard") transaction.

Geographic Revenues

BD’s worldwide ~~third~~second quarter revenues by geography were as follows:


	Three months ended June 30,										Three months ended March 31,
(Millions of dollars)	2019		2018		Total Change		Estimated FX Impact		FXN Change		2020		2019		Total Change		Estimated FX Impact		FXN Change
United States	$	2,440	$	2,338	4.4	%	—	%	4.4	%	$	2,415	$	2,341	3.2	%	—	%	3.2	%
International	1,910		1,941		(1.6	)%	(6.7	)%	5.1	%	1,839		1,854		(0.8	)%	(2.3	)%	1.5	%
Total Revenues	$	4,350	$	4,278	1.7	%	(3.0	)%	4.7	%	$	4,253	$	4,195	1.4	%	(1.0	)%	2.4	%

~~Third quarter~~ U.S. ~~revenues reflected growth in all three segments. Revenue~~revenue growth in the ~~current-year period~~second quarter of 2020 was largely attributable to sales in the Life Sciences segment's Integrated Diagnostic Solutions unit and sales in the Medical segment's Medication Delivery Solutions unit. Second quarter U.S. revenue growth was unfavorably impacted by results in the Medical segment's Medication Management Solutions unit, as ~~well as to sales in the Interventional segment's Urology and Critical Care unit. U.S.~~further discussed above.

Second quarter international revenue growth ~~in the third quarter of 2019~~ was ~~unfavorably impacted~~particularly driven by ~~results~~sales in the Medical segment's ~~Diabetes Care~~Pharmaceutical Systems unit and ~~the Interventional segment's Peripheral Intervention unit, as previously noted in the discussions above.~~

International revenues in the third quarter of 2019 reflected growth in all three segments. Third quarter international revenue growth in the Medical segment was particularly driven by growth in the Pharmaceutical Systems and Medication Delivery Solutions units as well as by growthsales in the Life Sciences segment's Integrated Diagnostic ~~Systems and Preanalytical Systems units.~~Solutions unit. International revenue growth in the second quarter of 2020 was unfavorably impacted by revenue declines in China for the Medical segment's Medication Delivery Solutions unit, as further discussed above.

Emerging market revenues for the ~~third~~second quarter were ~~$703~~$568 million, compared with ~~$689~~$637 million in the prior year’s quarter. Emerging market revenues in the current-year period ~~also~~ included an estimated ~~$47~~$19 million unfavorable impact due to foreign currency translation. ~~Third~~Second quarter ~~revenue growth~~revenues in emerging markets ~~was particularly driven~~were unfavorably impacted by ~~sales~~a decline in healthcare utilization in China ~~and EMA.~~as a result of the COVID-19 pandemic. As previously discussed above, revenues in our Medication Delivery Solutions unit were unfavorably impacted by a new volume-based procurement process which has been adopted by several of China's provinces. To date, the impact of these procurement initiatives to our revenues in China has been limited to our Medication Delivery Solutions unit.

Specified Items

Reflected in the financial results for the three and ~~nine-month~~six-month periods of fiscal years ~~2019~~2020 and ~~2018~~2019 were the following specified items:


	Three months ended June 30,						Nine months ended June 30,						Three months ended March 31,				Six months ended March 31,
(Millions of dollars)	2019			2018			2019			2018			2020		2019		2020		2019
Integration costs (a)	$	63		$	103		$	206		$	255		$	57	$	70	$	119	$	143
Restructuring costs (a)	27			33			99			288			18		31		41		72
Transaction costs ~~(a)~~	—			11			1			61			—		1		—		2
Financing impacts (b)	—			—			—			49
Purchase accounting adjustments (c)	378			433			1,135			1,358
Transaction gain/loss and product-related matters (d)	—			—			61			—
European regulatory initiative-related costs (e)	14			—			29			—
Purchase accounting adjustments (b)													340		379		688		757
Transaction gain/loss and product-related matters (c)													199		396		258		61
European regulatory initiative-related costs (d)													27		10		44		15
Investment gains/losses and asset impairments (e)													40		—		41		—
Impacts of debt extinguishment ~~(f)~~	52			3			53			16			—		1		—		1
Net impact of gain on sale of investment and asset impairments (g)	30			(214		)	30			(214		)
Hurricane recovery-related impacts	(10		)	3			(10		)	15
Total specified items	553			372			1,604			1,830			680		888		1,191		1,051
Less: tax impact of specified items and tax reform (h)	120			130			263			133
Less: tax impact of specified items and tax reform (f)													124		160		146		143
After-tax impact of specified items	$	432		$	242		$	1,341		$	1,697		$	557	$	729	$	1,045	$	908


(a)	Represents integration ~~restructuring~~ and ~~transaction~~restructuring costs which are primarily recorded in Acquisitions and other restructurings and are further discussed below.


(b)	~~Represents financing impacts associated with~~Includes amortization and other adjustments related to the ~~Bard acquisition, which were recorded in~~ ~~Interest income~~purchase accounting for acquisitions impacting identified intangible assets and ~~Interest expense~~.

~~(c)~~

~~Primarily represents non-cash amortization expense associated with acquisition-related identifiable intangible assets.~~ valuation of fixed assets and debt. BD’s amortization expense is primarily recorded in Cost of products sold. ~~The three and nine-month amounts in 2018 also included fair value step-up adjustments of $56 million and $478 million, respectively, relating to Bard's inventory on the acquisition date.~~

~~(d)~~(c)

~~Represents~~The amounts in the three and six-month periods of fiscal year 2020 included a $199 million charge recognized by the Medical segment in Cost of products sold to record a probable estimate of future costs associated with incremental remediation efforts, as further discussed below. The amount in the six-month period of fiscal year 2020 additionally included a $59 million charge recognized in the first quarter by the Medical segment in Cost of products sold to record estimated remediation costs. The amounts in the prior-year periods included a charge relating to certain product liability matters and the estimated cost of a product recall, as ~~well as~~noted above in the discussion regarding the Medical segment's income. These amounts were recorded to Other operating expense, net. The amount in the prior-year six-month period also included the pre-tax gain recognized in Other operating expense, net on BD's sale of its Advanced Bioprocessing business. ~~Further discussion regarding these amounts recorded to~~ ~~Other operating expense, net~~ ~~is provided below.~~


~~(e)~~(d)	Represents initial costs required to develop processes and systems to comply with emerging regulations such as the European Union Medical Device Regulation ("EUMDR") and General Data Protection Regulation ("GDPR"). These costs were recorded in Cost of products sold and Research and development ~~expense.~~expense.


~~(f)~~	~~Represents the impacts, which were primarily recorded in~~ ~~Other income (expense), net,~~ ~~of our extinguishment of certain long-term senior notes.~~

~~(g)~~(e)

The amounts in ~~2019~~2020 primarily represented a ~~non-cash~~ charge of $39 million recorded in Cost of products sold to write down the carrying value of certain intangible assets in the ~~Surgery unit. The amounts in 2018 included the net amount, recognized in the period and recorded to~~ ~~Other income (expense), net,~~ related to BD's sale of its non-controlling interest in Vyaire Medical, partially offset by $81 million of charges recorded to write down the carrying value of certain intangible and other assets in the Biosciences unit.


~~(h)~~(f)	The ~~amounts~~amount in the ~~nine-month periods~~six-month period of fiscal ~~years~~year 2019 ~~and 2018~~ included additional tax ~~(benefit)~~ expense, net, of ~~$(54)~~$20 million ~~and $275 million, respectively,~~ relating to new U.S. tax legislation, as further discussed below.

Gross Profit Margin

Gross profit margin for the three and ~~nine-month~~six-month periods of fiscal year ~~2019~~2020 compared with the prior-year periods in fiscal year ~~2018~~2019 reflected the following impacts:


	Three-month period		Nine-month period		Three-month period		Six-month period
June 30, 2018 gross profit margin %	47.1	%	44.7	%
March 31, 2019 gross profit margin %					47.1	%	47.2	%
Impact of purchase accounting adjustments and other specified items	3.1	%	3.6	%	(5.7	)%	(3.3	)%
Operating performance	(1.2	)%	0.2	%	(1.1	)%	(0.3	)%
Foreign currency translation	(1.3	)%	(1.1	)%	0.5	%	0.2	%
June 30, 2019 gross profit margin %	47.7	%	47.4	%
March 31, 2020 gross profit margin %					40.8	%	43.8	%

The ~~impact~~impacts of purchase accounting adjustments and other specified items oninclude the ~~current-year~~following:

•

The impacts in the three and six-month periods include a charge of $199 million to record a probable estimate of future costs within the Medication Management Solutions unit associated with incremental remediation efforts related to Alaris^TM infusion pumps. Based on the course of our remediation efforts, it is possible that this estimate could increase over time. Any remediation actions will continue to be guided by our proactive commitment to patient safety and we will work closely with our customers to minimize the disruption of patient care.

The impacts in the three and ~~nine-month~~six-month periods ~~was favorable due~~also include a $39 million charge to ~~a comparison to~~write down the ~~prior-year periods, which included the recognition of fair~~carrying value ~~step-up adjustments relating to Bard's inventory on the acquisition date, as well as write-downs~~ of certain intangible ~~and other~~ assets in the Biosciences ~~unit, as previously discussed above.~~ unit.


•	The impact in the six-month period additionally includes a $59 million charge recognized in the first quarter by the Medical segment to record estimated product remediation costs related to the Alaris^TM infusion pumps.

Operating performance for the three-month ~~period~~and six-month periods primarily reflected ~~the impact of~~ unfavorable product mix, some of which was attributable to the COVID-19 pandemic, and increased tariffs, partially offset by lower manufacturing costs resulting from continuous operations improvement projects and synergy initiatives. ~~Operating performance~~For the remainder of fiscal year 2020, the COVID-19 pandemic will place pressure on our gross margin due to declines in ~~the current-year nine-month period primarily reflected the favorable impact~~sales of ~~Bard on product mix as well as lower manufacturing costs resulting from continuous operations improvement projects and synergy initiatives, partially offset by~~products with higher ~~raw material costs and pricing pressures.~~

gross margins.

Operating Expenses

A summary of operating expenses for the three and ~~nine-month~~six-month periods of fiscal years ~~2019~~2020 and ~~2018~~2019 is as follows:


	Three months ended June 30,						Increase (decrease) in basis points			Nine months ended June 30,								Increase (decrease) in basis points		Three months ended March 31,						Increase (decrease) in basis points		Six months ended March 31,						Increase (decrease) in basis points
	2019			2018					2019				2018				2020				2019				2020			2019						Increase (decrease) in basis points
(Millions of dollars)							Increase (decrease) in basis points											Increase (decrease) in basis points
Selling and administrative expense	$	1,076		$	1,086					$	3,238			$	2,915					$	1,025		$	1,089		Increase (decrease) in basis points			$	2,146		$	2,161
% of revenues	24.7		%	25.4		%	(70	)		25.5		%		25.2		%		30		24.1		%	25.9		%	(180	)	25.3		%	25.9		%	(60	)

Research and development expense	$	282		$	277					$	792			$	727					$	264		$	252				$	535		$	510
% of revenues	6.5		%	6.5		%	—			6.2		%		6.3		%		(10	)	6.2		%	6.0		%	20		6.3		%	6.1		%	20

Acquisitions and other restructurings	$	90		$	142					$	281			$	600					$	75		$	101				$	161		$	191

Other operating expense, net	$	—		$	—					$	61			$	—					$	—		$	396				$	—		$	61

Selling and administrative expense

The ~~decrease~~decreases in selling and administrative expense as a percentage of revenues in the current ~~three-month period~~three and six-month periods compared with the prior-year periods primarily reflected ~~higher revenues and the achievement of cost synergies~~a decrease in the ~~current year's quarter.~~deferred compensation plan liability due to market performance. The ~~increase~~losses on investment assets result in ~~selling~~a favorable impact on expense recorded in Selling and administrative expense. Selling and administrative expense as a percentage of revenues in the ~~current nine-month period compared with the prior-year period primarily reflected~~current-year periods was unfavorably impacted by higher ~~selling and general administrative costs attributable to Bard, which had a higher selling~~shipping costs. Selling and administrative ~~spending profile than BD,~~expense as a percentage of revenues in the ~~current-year's first quarter results.~~current-year periods also reflected our ongoing focus on disciplined spending and the achievement of cost synergies resulting from our acquisition of Bard, as well as a favorable impact from the cost containment measures we have enacted to mitigate the impact of the COVID-19 pandemic on our results of operations.

Research and development expense

Research and development expense as a percentage of revenues in the ~~current~~ three and ~~nine-month~~six-month periods was ~~relatively flat~~higher compared with the prior-year ~~periods.~~periods primarily due to higher costs incurred to achieve compliance with emerging regulations, as further discussed above. Spending in both the current and prior-year periods reflected our continued commitment to ~~invest in~~drive innovation with new products and platforms. Expense in the current-year periods also included a charge recorded to write down the carrying value of certain intangible assets in the Surgery unit and expense in the prior-year periods included certain write-down charges in the Biosciences unit, as noted above.

Acquisitions and other restructurings

Costs relating to acquisitions and other restructurings in the ~~current year's~~ three and ~~nine-month~~six-month periods of 2020 and 2019 largely represented integration and restructuring costs incurred due to our acquisition of Bard in the first quarter of fiscal year 2018. Costs relating to acquisitions and other restructurings in the prior year's three and nine-month periods included restructuring, integration and transaction costs incurred due to our acquisition of Bard as well as integration and restructuring costs related to our CareFusion acquisition and other portfolio rationalization initiatives. For further disclosures regarding restructuring costs, refer to Note 1110 in the Notes to Condensed Consolidated Financial Statements.

Other operating expense, net

Other operating expense in the ~~current nine-month period~~prior-year periods included a charge of approximately $331 million relating to certain product liability matters as further discussed in Note 5 in the Notes to Condensed Consolidated Financial ~~Statements, as well as~~Statements. The amounts in the period-year periods also included the estimated costs of $65 million relating to a product recall, as noted above in the discussion regarding the Medical ~~segment. Net other operating expense~~segment's income. The amount in the ~~current nine-month~~prior-year six-month period additionally included the pre-tax gain of ~~$336~~$335 million recognized on BD's sale of its Advanced Bioprocessing ~~business. Additional disclosures regarding this divestiture transaction are provided in Note 10~~business in the ~~Notes to Condensed Consolidated Financial Statements.~~

first quarter of fiscal year 2019.

Nonoperating Income

Net interest expense

The components for the three and ~~nine-month~~six-month periods of fiscal years ~~2019~~2020 and ~~2018~~2019 were as follows:


	Three months ended June 30,						Nine months ended June 30,						Three months ended March 31,						Six months ended March 31,
(Millions of dollars)	2019			2018			2019			2018			2020			2019			2020			2019
Interest expense	$	(156	)	$	(182	)	$	(498	)	$	(525	)	$	(134	)	$	(171	)	$	(270	)	$	(342	)
Interest income	2			8			8			55
Interest income, net													2			18			3			6
Net interest expense	$	(154	)	$	(174	)	$	(490	)	$	(470	)	$	(132	)	$	(153	)	$	(267	)	$	(336	)

Lower interest expense in the current year's three and ~~nine-month~~six-month periods compared with the prior-year periods primarily reflected ~~higher fees incurred in the prior-year period to draw from our term loan facility, which is further discussed below. Interest expense in the current-year periods was also favorably impacted by~~ debt repayments during ~~the current~~fiscal year 2019, as well as lower overall interest rates on debt outstanding during the current-year ~~period~~periods as a result of ~~refinancing activities.~~

~~Interest income was not material to our consolidated financial results in the current and prior-year three-month periods. The decrease in interest income for the nine-month period of~~ fiscal year 2019 ~~reflected higher levels of cash on hand in the first quarter of fiscal year 2018 in anticipation of closing the Bard acquisition at the end of the quarter.~~

~~Other income (expense), net~~

~~The components of~~ ~~Other income (expense), net~~ ~~for the three and nine-month periods of fiscal years 2019 and 2018 were largely not material to our consolidated financial results. Other income in the three and nine-month periods of fiscal year 2018included a net amount related to BD's sale of its non-controlling interest in Vyaire Medical, as noted above.~~refinancing activities.

Income Taxes

The income tax rates for the three and ~~nine-month~~six-month periods of fiscal years ~~2019~~2020 and ~~2018~~2019 are provided below.


	Three months ended June 30,				Nine months ended June 30,				Three months ended March 31,				Six months ended March 31,
	2019		2018		2019		2018		2020		2019		2020		2019
Effective income tax rate	2.0	%	8.2	%	9.1	%	41.2	%	8.5	%	(540.4	)%	22.5	%	13.7	%

Impact, in basis points, from specified items and tax reform	(1,080	)	(980	)	(420	)	2,400		(750	)	(55,640	)	680		10

The effective income tax ~~rate~~rates for the ~~three-month period~~three and six-month periods of fiscal year ~~2019~~2020 reflected ~~a more favorable~~ tax ~~impact~~impacts from specified items ~~and tax reform~~that were less favorable compared with the ~~benefit~~benefits associated with specified items recognized in the prior-year ~~period.~~periods. The effective income tax rate for the ~~nine-month~~six-month period of fiscal year 2019 reflected ~~a favorable impact relating to the timing of certain discrete items, as well as~~ the recognition of ~~$54~~additional tax expense of $20 million ~~of tax benefit recorded to adjust our consolidated balance sheet for the impacts~~as a result of U.S. tax legislation that was enacted in December ~~2017, compared with additional~~2017. The effective income tax ~~expense~~rate for the six-month period of ~~$275 million that~~fiscal year 2019 was ~~recognized as a result~~favorably impacted by the timing of this legislation in the prior-year period. For further disclosures regarding the finalization of our accounting for this U.S. tax legislation, refer to Note 16 in the Notes to Condensed Consolidated Financial Statements.certain discrete items.

Net Income and Diluted Earnings per Share

Net Income and Diluted Earnings per Share for the three and ~~nine-month~~six-month periods of fiscal years ~~2019~~2020 and ~~2018~~2019 were as follows:

Three months ended June 30, Nine months ended June 30,
2019 2018 2019 2018
Net Income (Millions of dollars) $ 451
$ 594
$ 1,071
$ 446
Diluted Earnings per Share $ 1.51
$ 2.03
$ 3.49
$ 1.27

Unfavorable impact-specified items $ (1.58 ) $ (0.88 ) $ (4.88 ) $ (6.51 )
Dilutive impact of BD shares $ —
$ —
$ —
$ (0.31 )
Unfavorable impact-foreign currency translation $ (0.25 ) $ (0.64 )



	Three months ended March 31,						Six months ended March 31,
	2020			2019			2020			2019
Net Income (Millions of dollars)	$	183		$	20		$	461		$	619
Diluted Earnings (Loss) per Share	$	0.53		$	(0.07	)	$	1.40		$	1.98

Unfavorable impact-specified items	$	(2.02	)	$	(2.70	)	$	(3.80	)	$	(3.31	)
Dilutive impact of BD shares	$	—		$	0.04		$	—		$	—
Favorable (unfavorable) impact-foreign currency translation	$	0.01					$	(0.03	)

The dilutive impact for the ~~nine-month~~three-month period of fiscal year ~~2018 included~~2019 represented the ~~unfavorable~~ impact of BDshare equivalents associated with share-based plans that were excluded from the reported diluted shares ~~issued through public offerings of equity securities in~~outstanding calculation because the ~~third quarter of fiscal year 2017, in anticipation of the Bard acquisition, and BD shares issued as consideration transferred in the first quarter of fiscal year 2018 for the Bard acquisition.~~result would have been antidilutive.

Liquidity and Capital Resources

The following table summarizes our condensed consolidated statements of cash flows:

Nine months ended June 30,
(Millions of dollars) 2019 2018
Net cash provided by (used for)
Operating activities $ 1,959
$ 1,559
Investing activities $ (300 ) $ (15,173 )
Financing activities $ (2,300 ) $ 949

Cash generated from operations, along with available cash and cash equivalents, is expected to be sufficient to fund our normal operating needs for the remainder of fiscal year 2019. Normal operating needs in fiscal year 2019 include working capital, capital expenditures, and cash dividends.



	Six months ended March 31,
(Millions of dollars)	2020			2019
Net cash provided by (used for)
Operating activities	$	1,196		$	1,027
Investing activities	$	(542	)	$	30
Financing activities	$	1,210		$	(1,532	)

Net Cash Flows from Operating Activities

Cash flows from operating activities in the first ~~nine~~six months of fiscal year ~~2019~~2020 reflected net income, adjusted by a change in operating assets and liabilities that was a net use of cash. This net use of cash primarily reflected higher levels of inventory and lower levels of accounts payable and accrued expenses, ~~and higher levels of inventory,~~ partially offset by lower levels of trade ~~receivables. Accounts payable~~receivables and ~~accrued expenses were lower primarily due to the timing and amount of interest payments due as well as cash paid related to our product liability matters and income taxes payable.~~ prepaid expenses.

Cash flows from operating activities in the ~~current-year period were~~first six months of fiscal year 2019 reflected net income, adjusted by ~~the charge~~a change in operating assets and liabilities that was a net use of ~~$331 million relating to certain product liability matters, which is noted above and further discussed in Note 5 in the Notes to Condensed Consolidated Financial Statements.~~cash. Cash flows from operating activities in the ~~current-year~~prior-year period additionally reflected ~~an adjustment for a gain of $336 million on our sale of a business, which is further discussed in Note 10 in the Notes to Condensed Consolidated Financial Statements, as well as~~ $200 million of discretionary cash contributions to fund our pension obligation.

Cash flows from operating activities in the prior-year period reflected a non-cash change to deferred tax asset and liability balances which were remeasured during the prior-year period under new tax legislation, as further discussed above. Cash flows from operating activities in the prior-year period additionally reflected a change in operating assets and liabilities that was a net source of cash, a $308 million gain on the sale of our remaining interest in the Vyaire Medical venture, as well as discretionary cash contributions to fund our pension obligation of $287 million.

Net Cash Flows from Investing Activities

Our investments in capital expenditures are focused on projects that enhance our cost structure and manufacturing capabilities, and support our strategy of geographic expansion with select investments in growing markets. As part of the cost containment measures we have enacted in response to the COVID-19 pandemic, we are currently prioritizing spending for only our most critical capital projects. Net outflows from investing activities in the first ~~nine~~six months of fiscal year ~~2019~~2020 included capital expenditure-related outflows of ~~$599~~$395 million, compared with ~~$588~~$362 million in the prior-year period. Net cash flows from investing activities in the first ~~nine~~six months of fiscal year 2019 also included proceeds $477 million ~~of proceeds~~ from our sale of a business during the period, as further discussed ~~above, compared with $534 million of proceeds from divestitures in the prior-year period. Cash outflows for acquisitions in the prior-year period of $15.0 billion related to our acquisition of Bard.~~

above.

Net Cash Flows from Financing Activities

Net cash from financing activities in the first ~~nine~~six months of fiscal years ~~2019~~2020 and ~~2018~~2019 included the following significant cash flows:


	Nine months ended June 30,						Six months ended March 31,
(Millions of dollars)	2019			2018			2020			2019
Cash inflow (outflow)
Change in credit facility borrowings	$	300		$	200		$	210		$	—
Proceeds from long-term debt and term loans	$	2,224		$	4,335		$	1,900		$	—
Payments of debt and term loans	$	(3,882	)	$	(2,723	)	$	(305	)	$	(905	)
Dividends paid	$	(737	)	$	(687	)	$	(505	)	$	(491	)

Certain measures relating to our total debt were as follows:


(Millions of dollars)	June 30, 2019			September 30, 2018			March 31, 2020			September 30, 2019
Total debt	$	20,184		$	21,496		$	21,167		$	19,390

Short-term debt as a percentage of total debt	10.7		%	12.1		%	20.6		%	6.8		%
Weighted average cost of total debt	2.9		%	3.2		%	2.7		%	2.9		%
Total debt as a percentage of total capital*	45.9		%	47.8		%	48.1		%	45.6		%

* Represents shareholders’ equity, net non-current deferred income tax liabilities, and debt.

The ~~decrease~~increase in the ratio of short-term debt as a percentage of total debt at ~~June 30, 2019~~March 31, 2020 was primarily driven by ~~the payment~~our reclassification of certain notes from long-term to short-term ~~notes as well as the issuance of long-term notes in 2019. Further disclosures regarding these transactions are provided in Note 15 in the Notes to Condensed Consolidated Financial Statements.~~and by borrowings under a term loan agreement which is further discussed below.

Cash and Short-term Investments

At ~~June 30, 2019,~~March 31, 2020, total worldwide cash and short-term investments, including restricted cash, were approximately ~~$606 million,~~$2.445 billion, which were primarily held in ~~jurisdictions outside of~~ the United States.

Financing Facilities

~~In September 2018,~~While we ~~entered into~~deemed our liquidity sufficient to fund our operations and meet our obligations prior to taking these actions, BD has taken steps as a ~~364-day $750 million senior unsecured term loan facility. Borrowings outstanding under~~precautionary measure to preserve our financial flexibility in light of the ~~term loan facility were $35 million at June 30, 2019.~~uncertainty in the global markets resulting from the COVID-19 pandemic. We ~~also~~ have a five-year senior unsecured revolving credit facility in place which ~~provides borrowing of up to $2.25 billion. This facility~~ will expire in December 2022. ~~We are able to issue up to $100 million in letters of credit under this new revolving credit~~The facility ~~and it also~~agreement includes a provision that ~~enables~~enabled BD, subject to additional commitments made by the lenders, to access up to an additional $500 million in financing through the facility for a maximum aggregate commitment of $2.75 billion. In April 2020, we entered into a supplement to the facility agreement which increased the revolving commitments available under the facility by $381 million. As such, borrowings provided for under the agreement increased from $2.25 billion to $2.63 billion. We are also able to issue up to $100 million in letters of credit under this revolving credit facility. We use proceeds from this facility to fund general corporate needs. Borrowings outstanding under the revolving credit facility at ~~June 30, 2019~~March 31, 2020 were ~~$300~~$695 million.

The ~~agreements~~agreement for our ~~term loan and~~ revolving credit facility and the supplement entered into in April 2020 contained the following financial covenants. We were in compliance with these covenants as of ~~June 30, 2019.~~March 31, 2020.

We are required to maintain an interest expense coverage ratio of not less than 4-to-1 as of the last day of each fiscal quarter.

We are required to have a leverage coverage ratio ~~as applicable depending upon commencement and maturity of the facility,~~ of no more than:


◦	6-to-1 from the closing date of the Bard acquisition until and including the first fiscal quarter-end thereafter;


◦	5.75-to-1 for the subsequent four fiscal quarters thereafter;


◦	5.25-to-1 for the subsequent four fiscal quarters thereafter;


◦	4.5-to-1 for the subsequent four fiscal quarters thereafter;


◦	4-to-1 for the subsequent four fiscal quarters thereafter;


◦	3.75-to-1 thereafter.

In March 2020, we entered into a 364-day $1.4 billion senior unsecured term loan facility and later in March 2020, we amended this agreement to increase the borrowing capacity available under the facility to $2.0 billion. Borrowings under the term loan facility will primarily be used to supplement our cash position. Borrowings outstanding under the 364-day term loan facility were $1.9 billion at March 31, 2020. The agreement for our term loan facility and the amendment to the facility contained the following financial covenants. We were in compliance with these covenants as of March 31, 2020.

We are required to maintain an interest expense coverage ratio of not less than 4-to-1 as of the last day of any fiscal quarter.

We are required to have a leverage ratio of not greater than:


◦	5.25-to-1 from the effectiveness of the Term Loan Agreement until and including the last day of the fiscal quarter ending March 31, 2020;


◦	4.5-to-1 as of the last day of any fiscal quarter thereafter.

We also have informal lines of credit outside the United States. ~~The Company had no commercial paper borrowings outstanding as of June 30, 2019.~~ We may, from time to time, access the commercial paper market and/or sell certain trade receivable assets to third parties as we manage working capital over the normal course of our business ~~activities.~~

activities. We had no commercial paper borrowings outstanding as of March 31, 2020. Additional disclosures regarding sales of trade receivable assets are provided in Note 13 in the Notes to Condensed Consolidated Financial Statements.

Access to Capital and Credit Ratings

Our corporate credit ratings with the rating agencies ~~Standard & Poor's Ratings Services~~Moody's Investor Service and Fitch Ratings at ~~June 30, 2019~~March 31, 2020 were unchanged compared with our ratings at September 30, ~~2018.~~2019. In ~~May 2019, Moody's Investor Service reaffirmed~~March 2020, Standard & Poor's Ratings Services affirmed our September 30, ~~2018~~2019 ratings and revised the agency's outlook regarding the likely direction of these ratings ~~over the medium term~~ from Stable to ~~Positive.~~Negative.

Lower corporate debt ratings and downgrades of our corporate credit ratings or other credit ratings may increase our cost of borrowing. We believe that given our debt ratings, our financial management policies, our ability to generate cash flow and the non-cyclical, geographically diversified nature of our businesses, we would have access to additional short-term and long-term capital should the need arise. A rating reflects only the view of a rating agency and is not a recommendation to buy, sell or hold securities. Ratings can be revised upward or downward at any time by a rating agency if such rating agency decides that circumstances warrant such a change.

Concentrations of Credit Risk

We continually evaluate our accounts receivables for potential collection risks, particularly those resulting from sales to government-owned or government-supported healthcare facilities in certain countries, as payment may be dependent upon the financial stability and creditworthiness of those countries’ national economies. We continually evaluate all governmental receivables for potential collection risks associated with the availability of government funding and reimbursement practices. We believe the current reserves related to all governmental receivables are adequate and that these receivables will not have a material adverse impact on our financial position or liquidity.

To date, we have not experienced a significant increased risk of collectability of accounts receivables in general as a result of the COVID-19 pandemic. No assurances can be given that the risk of collectability will not increase in the future given the uncertainty around the duration of the pandemic and its economic impact.

Regulatory Matters

In January 2018, BD received a Warning Letter from the U.S. FDA, citing certain alleged violations of quality system regulations and of law with respect to our Preanalytical Systems facility in Franklin Lakes, New Jersey. The Warning Letter states that, until BD resolves the outstanding issues covered by the Warning Letter, the FDA will not clear or approve any premarket submissions for Class III devices to which the non-conformances are reasonably related or grant requests for certificates to foreign governments. BD is working closely with the FDA and intends to fully implement corrective actions to address the concerns identified in the Warning Letter. However, BD cannot give any assurances that the FDA will be satisfied with its responses to the Warning Letter or as to the expected date of resolution of matters included in the Warning Letter. While BD does not believe that the issues identified in the Warning Letter will have a material impact on BD’s operation, no assurances can be given that the resolution of this matter will not have a material adverse effect on BD’s business, results of operations, financial conditions and/or liquidity.

In October 2019, BD entered into a consent order with the Environmental Protection Division of the Georgia Department of Natural Resources (“EPD”), following the filing of a complaint and motion for temporary restraining order by the EPD seeking to enjoin BD from continuing sterilization operations at its Covington, Georgia facility. Under the terms of the consent order, BD voluntarily agreed to a number of operational changes at its Covington and Madison, Georgia facilities designed to further reduce ethylene oxide emissions, including but not limited to operating at a reduced capacity. BD does not believe that the consent order will have a material impact on its operations. Violation of the consent order could subject us to additional restrictions on the sterilization operations at our Covington and Madison facilities. BD has business continuity plans in place to mitigate the impact of any additional restrictions on our operations at these facilities, although it is possible that these plans will not be able to fully offset such impact.

As previously reported, our Alaris^TM infusion pump organizational unit is operating under an amended consent decree entered into by CareFusion that includes all infusion pumps manufactured by or for CareFusion 303, Inc., the organizational unit that manufactures and sells Alaris^TM infusion pumps in the United States. Following an inspection that began in March 2020 of our Medication Management Systems facility (CareFusion 303, Inc.) in San Diego, California, the FDA issued to BD a Form 483 Notice that contains a number of observations of non-conformance. BD has provided the FDA with its response to the Form 483 and has begun to implement certain corrective actions to address the observations. However, the FDA’s review of the items raised in the Form 483 remains ongoing and no assurances can be given regarding further action by the FDA as a result of the observations.

Cautionary Statement Regarding Forward-Looking Statements

This report includes forward-looking statements within the meaning of the federal securities laws. BD and its representatives may also, from time to time, make certain forward-looking statements in publicly released materials, both written and oral, including statements contained in filings with the Securities and Exchange Commission, press releases, and our reports to shareholders. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,”, “may”, “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth, and cash flows) and statements regarding our strategy for growth, future product development, regulatory approvals, competitive position and expenditures. All statements that address our future operating performance or events or developments that we expect or anticipate will occur in the future are forward-looking statements.

Forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events, developments and operating performance, and speak only as of their dates. Investors should realize that if underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements. Furthermore, we undertake no obligation to update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events and developments or otherwise, except as required by applicable law or regulations.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements. For further discussion of certain of these factors, see Item 1A. Risk Factors in this report and in our ~~2018~~2019 Annual Report on Form 10-K.

~~Weakness~~Any negative impact of the COVID-19 pandemic on our business, including, without limitation, decreases in the demand for our products or disruptions to our operations and our supply chain.

The current weakness in the global economy and financial markets, which could increase the cost of operating our business, weaken demand for our products and services, negatively impact the prices we can charge for our products and services, or impair our ability to produce our products.

Competitive factors that could adversely affect our operations, including new product introductions and technologies (for example, new forms of drug delivery) by our current or future competitors, consolidation or strategic alliances among healthcare companies, distributors and/or payers of healthcare to improve their competitive position or develop new models for the delivery of healthcare, increased pricing pressure due to the impact of low-cost manufacturers, patents attained by competitors (particularly as patents on our products expire), ~~and~~ new entrants into our ~~markets.~~markets and changes in the practice of medicine.

Risks relating to our acquisition of Bard, including our ability to successfully combine and integrate the Bard operations in order to obtain the anticipated benefits and costs savings from the transaction, and the significant additional indebtedness we incurred in connection with the financing of the acquisition and the impact ~~this increased indebtedness~~it may have on our ability to operate the combined company.

The adverse financial impact resulting from unfavorable changes in foreign currency exchange rates.

Regional, national and foreign economic factors, including inflation, deflation, and fluctuations in interest rates, and their potential effect on our operating performance.

Our ability to achieve our projected level or mix of product sales, as our earnings forecasts are based on projected sales volumes and pricing of many product types, some of which are more profitable than others.

Changes in reimbursement practices of governments or third-party payers, or adverse decisions relating to our products by such payers, which could reduce demand for our products or the price we can charge for such products.

The impact of the medical device excise tax under the Patient Protection and Affordable Care Act in the United States. While this tax has been suspended through December 31, 2019, it is uncertain whether the suspension will be extended beyond that date.

~~Healthcare reform~~Cost containment efforts in the U.S. or in other countries in which we do business, ~~that may involve changes~~such as alternative payment reform and increased use of competitive bidding and tenders, including, without limitation, any expansion of the volume-based procurement process in ~~government pricing and reimbursement policies or other cost containment reforms.~~China.

Changes in the domestic and foreign healthcare industry or in medical practices that result in a reduction in procedures using our products or increased pricing pressures, including the continued consolidation among healthcare ~~providers and trends toward managed care and healthcare cost containment.~~providers.

The impact of changes in U.S. federal laws and policy that could affect fiscal and tax policies, healthcare, and international trade, including import and export regulation and international trade agreements. ~~Recently, the U.S., China and other countries have imposed tariffs on certain products imported into their respective countries. Additional~~In particular, tariffs or other trade barriers imposed by the U.S.~~, China~~ or other countries could adversely impact our supply chain costs or otherwise adversely impact our results of operations.

~~Fluctuations~~

Increases in operating costs, including fluctuations in the cost and availability of oil-based resins and other raw materials, as well as certain components, used in our products, the ability to maintain favorable supplier arrangements and relationships (particularly with respect to sole-source suppliers), and the potential adverse effects of any disruption in the availability of such items.

Security breaches of our information technology systems or our products, which could impair our ability to conduct business, result in the loss of BD trade secrets or otherwise compromise sensitive information of BD or its customers, suppliers and other business partners, or of customers' patients, or result in product efficacy or safety concerns for certain of our products, and result in actions by regulatory bodies or civil litigation.

Difficulties inherent in product development, including the potential inability to successfully continue technological innovation, successfully complete clinical trials, obtain regulatory approvals in the United States and abroad, obtain intellectual property protection for our products, obtain coverage and adequate reimbursement for new products, or gain and maintain market approval of products, as well as the possibility of infringement claims by competitors with respect to patents or other intellectual property rights, all of which can preclude or delay commercialization of a product. Delays in obtaining necessary approvals or clearances from ~~FDA~~United States Food and Drug Administration (“FDA”) or other regulatory agencies or changes in the regulatory process may also delay product launches and increase development costs.

The impact of business combinations or divestitures, including any volatility in earnings relating to acquisition-related costs, and our ability to successfully integrate any business we may acquire.

Our ability to penetrate or expand our operations in emerging markets, which depends on local economic and political conditions, and how well we are able to make necessary infrastructure enhancements to production facilities and distribution networks.

Conditions in international markets, including social and political conditions, civil unrest, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders, tariffs and other protectionist measures, difficulties in protecting and enforcing our intellectual property rights and governmental expropriation of assets. This includes the possible impact of the United Kingdom's exit from the European Union ("EU"), which has created uncertainties affecting our business operations in the United Kingdom and the EU, and possibly other countries. Our international operations also increase our compliance risks, including risks under the Foreign Corrupt Practices Act and other anti-corruption laws, as well as regulatory and privacy laws.

Conditions in international markets, including social and political conditions, civil unrest, terrorist activity, governmental changes, trade barriers, restrictions on the ability to transfer capital across borders, difficulties in

protecting and enforcing our intellectual property rights and governmental expropriation of assets. This includes the possible impact of the United Kingdom's exit from the European Union ("Brexit"), which has created uncertainties affecting our business operations in the United Kingdom and the EU, and possibly other countries, including with respect to compliance with the regulatory regimes regarding the labeling and registration of the products we sell in these markets. The limited progress in the negotiations of the terms of the U.K.’s withdraw and the possibility that the U.K. may exit the EU without a formal withdrawal agreement in place has increased the uncertainty around Brexit. While we have taken proactive steps to mitigate any disruption to our operations, we could face increased regulatory costs, volatility in exchange rates, market instability and other risks, depending on the final terms of the U.K.’s exit from the EU.

Deficit reduction efforts or other actions that reduce the availability of government funding for healthcare and research, which could weaken demand for our products and result in additional pricing pressures, as well as create potential collection risks associated with such sales.

Fluctuations in university or U.S. and international governmental funding and policies for life sciences research.

Fluctuations in the demand for products we sell to pharmaceutical companies that are used to manufacture, or are sold with, the products of such companies, as a result of funding constraints, consolidation or otherwise.

The effects of weather, regulatory or other events that adversely impact our supply chain, including our ability to manufacture our products (particularly where production of a product line isor sterilization operations are concentrated in one or more plants) or, source materials or components or services from suppliers (including sole-source suppliers) that are needed for such manufacturing (including sterilization), or ~~our ability to~~ provide products to our customers, including events that impact key distributors.

Natural disasters (including pandemics), war, terrorism, labor disruptions and international conflicts that could cause significant economic disruption and political and social instability, resulting in decreased demand for our products, adversely affect our manufacturing and distribution capabilities, or cause interruptions in our supply chain.

Pending and potential future litigation or other proceedings asserting, and/or subpoenas seeking information with respect to, alleged violations of law (including in connection with federal and/or state healthcare programs ~~such~~(such as Medicare or ~~Medicaid,~~Medicaid) and/or sales and marketing practices ~~such~~(such as investigative subpoenas and the civil investigative demands received by BD and Bard)), antitrust claims, product liability ~~claims~~ (which may involve lawsuits seeking class action status or seeking to establish multi-district litigation proceedings, including claims relating to our hernia repair implant products, surgical continence products for women and vena cava filter products), claims with respect to environmental matters, and patent infringement, ~~actions,~~ and the availability or collectability of insurance relating to any such claims.

New or changing laws and regulations affecting our domestic and foreign operations, or changes in enforcement practices, including laws relating to trade, monetary and fiscal policies, taxation (including tax reforms that could adversely impact multinational corporations), sales practices, environmental protection, price controls, and licensing

and regulatory requirements for new products and products in the postmarketing phase. In particular, the U.S. and other countries may impose new requirements regarding registration, labeling or prohibited materials that may require us to re-register products already on the market or otherwise impact our ability to market our products. Environmental laws, particularly with respect to the emission of greenhouse gases, are also becoming more stringent throughout the world, which may increase our costs of operations or necessitate changes in our manufacturing plants or processes or those of our suppliers, or result in liability to BD.

Product efficacy or safety concerns regarding our products resulting in product holds or recalls, regulatory action on the part of the FDA or foreign counterparts (including restrictions on future product clearances and civil penalties), declining sales and product liability claims, and damage to our reputation. As a result of the CareFusion acquisition, we are operating under a consent decree with the FDA relating to our U.S. infusion pump business. The consent decree authorizes the FDA, in the event of any violations in the future, to order us to cease manufacturing and distributing products, recall products or take other actions, and we may be required to pay significant monetary damages if we fail to comply with any provision of the consent decree. Also, in ~~March~~ 2019, the FDA ~~issued a~~ letter to healthcare professionals regarding the use of paclitaxel-coated devices in the treatment of peripheral artery disease ~~advising clinicians to consider using alternative treatments. We estimate that the FDA letter will lead to a fifty percent decrease~~resulted in decreased sales of BD’s drug-coated ~~balloons for~~balloons. While we have changed the ~~balance of fiscal year 2019 compared~~labeling on our products as required by the FDA and continue to ~~our original forecast, although~~work with the ~~actual impact could be greater. The~~FDA on patient data, the extent and duration of the impact from the FDA letter, ~~beyond fiscal year 2019,~~ and the likelihood of FDA approval of new drug-coated devices, is difficult to ~~predict, and no assurance can be given that it will not have a material impact on our results of operations in future periods.~~predict.

The effect of adverse media exposure or other publicity regarding BD’s business or operations, including the effect on BD’s reputation or demand for its products.

The effect of market fluctuations on the value of assets in BD’s pension plans and on actuarial interest rate and asset return assumptions, which could require BD to make additional contributions to the plans or increase our pension plan expense.

Our ability to obtain the anticipated benefits of restructuring programs, if any, that we may undertake.

Issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission.

The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in information reported since the end of the fiscal year ended September 30, ~~2018.~~2019.

Item 4. Controls and Procedures

An evaluation was carried out by BD’s management, with the participation of BD’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of BD’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of ~~June 30, 2019.~~March 31, 2020. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the design and operation of these disclosure controls and procedures were, as of the end of the period covered by this report, effective and designed to ensure that material information relating to BD and its consolidated subsidiaries would be made known to them by others within these entities.

There were no changes in our internal control over financial reporting during the fiscal quarter ended ~~June 30, 2019~~March 31, 2020 identified in connection with the above-referenced evaluation that have materially affected, or are reasonably likely to materially affect, BD’s internal control over financial reporting. On December 29, 2017, BD completed the acquisition of Bard and in our 2018 Annual Report on Form 10-K, we excluded Bard from our evaluation of internal control over financial reporting. This exclusion was in accordance with the U.S. Securities and Exchange Commission's general guidance that a recently acquired business may be omitted from the assessment scope for up to one year from the date of acquisition. BD has extended its oversight and monitoring processes that support our internal control over financial reporting, as well as our disclosure controls and procedures, to the acquired operations of Bard and we will incorporate Bard into our annual assessment of internal control over financial reporting for our fiscal year ending September 30, 2019.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are involved, both as a plaintiff and a defendant, in various legal proceedings which arise in the ordinary course of business, including product liability and environmental matters as set forth in our ~~2018~~2019 Annual Report on Form 10-K, and in Note 5 of the Notes to Condensed Consolidated Financial Statements in this ~~report.~~report, which is incorporated herein by reference. Since ~~March~~December 31, 2019, there have been no material developments with respect to the legal proceedings in which we are involved, except as provided below.

~~Filter Product Claims~~Other Legal Matters

On ~~May 31, 2019,~~April 27, 2020, three putative stockholders, including the ~~multi-district litigation (“MDL”) Court ceased accepting direct filings or transfers into~~named plaintiff in the ~~Filter Product Claims MDL~~Kabak complaint, filed motions to be appointed lead plaintiff and ~~remands~~ for ~~non-settled cases are expected~~their counsel to begin within the next three to six months. Trials are scheduled throughout 2019 and 2020 in certain state and federal courts. As of June 30, 2019, the Company entered into settlement agreements and/or settlement agreements in principle for approximately 4,200 cases.

Given the uncertain nature of litigation generally, BD is not able in all cases to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which BD is a party. In accordance with U.S. generally accepted accounting principles, BD establishes accrualsbe appointed lead counsel pursuant to the ~~extent probable future losses are estimable (in the case~~Private Securities Litigation Reform Act of environmental matters, without considering possible third-party recoveries). In view of the uncertainties discussed above, BD could incur charges in excess of any currently established accruals and, to the extent available, excess liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on BD’s consolidated results of operations and consolidated cash flows.1995. Those motions remain pending.

Item 1A. Risk Factors

There were no material changes during the period covered by this report in the risk factors previously disclosed in Part I, Item 1A, of our ~~2018~~2019 Annual Report on Form ~~10-K.~~10-K, except as set forth below.

We are subject to risks associated with public health threats, including the ongoing COVID-19 pandemic.

We are subject to risks associated with public health threats, including the COVID-19 pandemic. The outbreak of COVID-19 and actions taken by governments and the private sector to slow the spread of the virus have resulted in a global economic slowdown, and have caused healthcare systems to divert resources to managing the pandemic. As a result, we have experienced significant reductions in the demand for certain of our products, particularly due to the decline in elective medical procedures, which negatively impacted our revenues in the second quarter of fiscal year 2020. As the pandemic continues, we expect to continue to experience weakened demand for these products as a result of the reduction in elective and non-essential procedures, lower utilization of routine testing and related specimen collection, reduced capital spend by customers and reduced demand from research laboratories. While we have seen increases in demand for certain product lines during the pandemic, this increased demand may not be sufficient to offset the revenue declines in other areas. We also expect pressure on our margins due to lost sales of products with gross margins that are higher than the company average. Safety measures taken by governments to slow the spread of the virus or determinations that our or our suppliers’ facilities are not essential businesses could also result in closures or other restrictions that significantly disrupt our operations or those of distributors or suppliers in our supply chain. In addition, while we undertook certain financing activities as a precautionary measure during this economic slowdown, no assurance can be given that we will be able to access capital markets in the future without incurring significant costs and expense. The scope and duration of the outbreak, the pace at which government restrictions will be lifted or whether additional actions may be taken to contain the virus, the speed and extent to which global markets and utilization rates for our products recover from the disruptions caused by the pandemic, and the impact of these factors on our business, will depend on future developments that are highly uncertain and cannot be predicted with confidence.

To the extent COVID-19 adversely affects our operations and global economic conditions more generally, it may also have the effect of heightening many of the other risks described in the "Risk Factors" section included in our 2019 Annual Report on Form 10-K for the year ended September 30, 2019.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The table below sets forth certain information regarding our purchases of common stock of BD during the quarter ended ~~June 30, 2019.~~March 31, 2020.

Issuer Purchases of Equity Securities

For the three months ended June 30, 2019
Total Number of
Shares Purchased (1)

Average Price
Paid per
Share

Total Number of
Shares Purchased
as Part of
Publicly
Announced Plans
or Programs

Maximum Number
of Shares that May
Yet Be Purchased
Under the Plans or
Programs (2)
April 1 – 30, 2019 2,838
$ 251.16
—
7,857,742
May 1 – 31, 2019 222
224.17
—
7,857,742
June 1 – 30, 2019 —
—
—
7,857,742
Total 3,060
$ 249.20
—
7,857,742



For the three months ended March 31, 2020	Total Number of Shares Purchased (1)	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs (2)
January 1 – 31, 2020	1,229	$	279.21	—	7,857,742
February 1 – 29, 2020	376	256.87		—	7,857,742
March 1 – 31, 2020	—	—		—	7,857,742
Total	1,605	$	273.98	—	7,857,742


(1)	Consists of ~~3,060~~1,605 shares purchased during the quarter in open market transactions by the trust relating to BD’s Deferred Compensation and Retirement Benefit Restoration Plan and 1996 Directors’ Deferral Plan.


(2)	Represents shares available under a repurchase program authorized by the Board of Directors on September 24, 2013 for 10 million shares, for which there is no expiration date.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

Item 6. Exhibits


~~Exhibit 31~~	~~Certifications of Chief Executive Officer and Chief Financial Officer, pursuant to SEC Rule 13a - 14(a).~~


~~Exhibit 32~~	~~Certifications of Chief Executive Officer and Chief Financial Officer, pursuant to Rule 13a - 14(b) and Section 1350 of Chapter 63 of Title 18 of the U.S. Code.~~


~~Exhibit 101~~	The following materials from this report, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.

~~SIGNATURES~~

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.~~



	~~Becton, Dickinson and Company~~
	~~(Registrant)~~

~~Dated: August 6, 2019~~



	~~/s/ Christopher Reidy~~
	~~Christopher Reidy~~
	~~Executive Vice President, Chief Financial Officer and Chief Administrative Officer~~
	~~(Principal Financial Officer)~~

	~~/s/ Charles Bodner~~
	~~Charles Bodner~~
	~~Senior Vice President, Corporate Finance, and Chief Accounting Officer~~
	~~(Principal Accounting Officer)~~

~~INDEX TO EXHIBITS~~



~~Exhibit~~ ~~Number~~10.1		~~Description~~ 364-Day Term Loan Agreement, dated as of ~~Exhibits~~March 20, 2020, among Becton, Dickinson and Company, the banks named therein and Wells Fargo Bank, National Association, as administrative agent (incorporated by reference to Exhibit 10.1 of the registrant's Current Report on Form 8-K filed on March 23, 2020).

10.2		First Amendment to 364-Day Term Loan Agreement and Joinder Agreement, dated as of March 27, 2020, among Becton, Dickinson and Company, the banks named therein and Wells Fargo Bank, National Association, as administrative agent (incorporated by reference to Exhibit 10.1 of the registrant's Current Report on Form 8-K filed on April 2, 2020).

10.3		Joinder Agreement, dated as of March 31, 2020, among Becton, Dickinson and Company, the bank named therein and Wells Fargo Bank, National Association, as administrative agent (incorporated by reference to Exhibit 10.2 of the registrant's Current Report on Form 8-K filed on April 2, 2020).

31		Certifications of Chief Executive Officer and Chief Financial Officer, pursuant to SEC Rule 13a - 14(a).

32		Certifications of Chief Executive Officer and Chief Financial Officer, pursuant to Rule 13a - 14(b) and Section 1350 of Chapter 63 of Title 18 of the U.S. Code.

101		The following materials from this report, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



	Becton, Dickinson and Company
	(Registrant)

Dated: May 7, 2020



	/s/ Christopher Reidy
	Christopher Reidy
	Executive Vice President, Chief Financial Officer and Chief Administrative Officer
	(Principal Financial Officer)

	/s/ Thomas J. Spoerel
	Thomas J. Spoerel
	Vice President, Controller and Chief Accounting Officer
	(Principal Accounting Officer)

4341



Interest Rate and Maturity	Aggregate Principal Amount (Millions of dollars)
3.700% Notes due June 6, 2027	$	675
5.000% Notes due November 12, 2040	175
4.875% Notes due May 15, 2044	75
4.685% Notes due December 15, 2044	175
Total notes purchased	$	1,100